



IN THE DISTRICT COURT OF CLEVELAND COUNTY
STATE OF OKLAHOMA

Document split into multiple parts

PART J

STATE OF OKLAHOMA, ex rel.,)
MIKE HUNTER,)
ATTORNEY GENERAL OF OKLAHOMA,)

Plaintiff,)

vs.)

Case No. CJ-2017-816
Judge Thad Balkman

- (1) PURDUE PHARMA L.P.;)
- (2) PURDUE PHARMA, INC.;)
- (3) THE PURDUE FREDERICK COMPANY;)
- (4) TEVA PHARMACEUTICALS USA, INC.;)
- (5) CEPHALON, INC.;)
- (6) JOHNSON & JOHNSON;)
- (7) JANSSEN PHARMACEUTICALS, INC;)
- (8) ORTHO-MCNEIL-JANSSEN)
PHARMACEUTICALS, INC., n/k/a)
JANSSEN PHARMACEUTICALS;)
- (9) JANSSEN PHARMACEUTICA, INC.,)
n/k/a JANSSEN PHARMACEUTICALS, INC.;)
- (10) ALLERGAN, PLC, f/k/a ACTAVIS PLC,)
f/k/a ACTAVIS, INC., f/k/a WATSON)
PHARMACEUTICALS, INC.;)
- (11) WATSON LABORATORIES, INC.;)
- (12) ACTAVIS LLC; and)
- (13) ACTAVIS PHARMA, INC.,)
f/k/a WATSON PHARMA, INC.,)

Defendants.)

STATE OF OKLAHOMA } S.S.
CLEVELAND COUNTY }

FILED

MAY 23 2019

In the office of the
Court Clerk MARILYN WILLIAMS

PRETRIAL CONFERENCE ORDER

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
16133	Exhibit 49	Osborne, James Patrick Exhibit 49	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16134	Exhibit 50	Osborne, James Patrick Exhibit 50	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16135	Exhibit 51	Osborne, James Patrick Exhibit 51	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16136	Exhibit 52	Osborne, James Patrick Exhibit 52	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16137	Exhibit 53	Osborne, James Patrick Exhibit 53	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16138	Exhibit 54	Osborne, James Patrick Exhibit 54	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16139	Exhibit 55	Osborne, James Patrick Exhibit 55	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16140	Exhibit 56	Osborne, James Patrick Exhibit 56	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16141	Exhibit 57	Osborne, James Patrick Exhibit 57	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16142	Exhibit 58	Osborne, James Patrick Exhibit 58	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16143	Exhibit 59	Osborne, James Patrick Exhibit 59	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16144	Exhibit 60	Osporne, James Patrick Exhibit 60	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16145	Exhibit 5	Varalli-Claypool, Bruna Mae Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16146	Exhibit 6	Varalli-Claypool, Bruna Mae Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16147	Exhibit 11	Varalli-Claypool, Bruna Mae Exhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16148	Exhibit 12	Varalli-Claypool, Bruna Mae Exhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16149	Exhibit 16	Varalli-Claypool, Bruna Mae Exhibit 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16150	Exhibit 18	Varalli-Claypool, Bruna Mae Exhibit 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16151	Exhibit 19	Varalli-Claypool, Bruna Mae Exhibit 19	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16152	Exhibit 20	Varalli-Claypool, Bruna Mae Exhibit 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16153	Exhibit 22	Varalli-Claypool, Bruna Mae Exhibit 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16154	Exhibit 23	Varalli-Claypool, Bruna Mae Exhibit 23	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16155	Exhibit 27	Varalli-Claypool, Bruna MaeExhibit 27	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16156	Exhibit 28	Varalli-Claypool, Bruna MaeExhibit 28	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16157	Exhibit 35	Varalli-Claypool, Bruna MaeExhibit 35	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16158	Exhibit 38	Varalli-Claypool, Bruna MaeExhibit 38	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16159	Exhibit 39	Varalli-Claypool, Bruna MaeExhibit 39	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16160	Exhibit 40	Varalli-Claypool, Bruna MaeExhibit 40	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16161	Exhibit 46	Varalli-Claypool, Bruna MaeExhibit 46	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16162	Exhibit 58	Varalli-Claypool, Bruna MaeExhibit 58	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16163	Exhibit 59	Varalli-Claypool, Bruna MaeExhibit 59	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16164	Exhibit 60	Varalli-Claypool, Bruna MaeExhibit 60	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16165	Exhibit 61	Varalli-Claypool, Bruna MaeExhibit 61	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
16166	Exhibit 62	Varalli-Claypool, Bruna Mae Exhibit 62	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16167	Exhibit 63	Varalli-Claypool, Bruna Mae Exhibit 63	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16168	Exhibit 64	Varalli-Claypool, Bruna Mae Exhibit 64	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16169	Exhibit 65	Varalli-Claypool, Bruna Mae Exhibit 65	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16170	Exhibit 66	Varalli-Claypool, Bruna Mae Exhibit 66	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16171	Exhibit 67	Varalli-Claypool, Bruna Mae Exhibit 67	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16172	Exhibit 68	Varalli-Claypool, Bruna Mae Exhibit 68	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16173	Exhibit 69	Muchmore, John Exhibit 69	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16174	Exhibit 70	Muchmore, John Exhibit 70	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16175	Exhibit 71	Muchmore, John Exhibit 71	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16176	Exhibit 72	Muchmore, John Exhibit 72	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16177	Exhibit 73	Muchmore, John Exhibit 73	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16178	Exhibit 74	Muchmore, John Exhibit 74	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16179	Exhibit 75	Muchmore, John Exhibit 75	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16180	Exhibit 76	Muchmore, John Exhibit 76	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16181	Exhibit 77	Muchmore, John Exhibit 77	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16182	Exhibit 78	Muchmore, John Exhibit 78	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16183	Exhibit 79	Muchmore, John Exhibit 79	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16184	Exhibit 80	Muchmore, John Exhibit 80	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16185	Exhibit 81	Muchmore, John Exhibit 81	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16186	Exhibit 82	Muchmore, John Exhibit 82	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16187	Exhibit 83	Muchmore, John Exhibit 83	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
16188	Exhibit 84	Muchmore, John Exhibit 84	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16189	Exhibit 1	Nesser, Nancy Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16190	Exhibit 2	Nesser, Nancy Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16191	Exhibit 3	Nesser, Nancy Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16192	Exhibit 4	Nesser, Nancy Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16193	Exhibit 5	Nesser, Nancy Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16194	Exhibit 6	Nesser, Nancy Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16195	Exhibit 1	McCurdy, Joel M.D Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16196	Exhibit 2	McCurdy, Joel M.D Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16197	Exhibit 3	McCurdy, Joel M.D Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16198	Exhibit 4	McCurdy, Joel M.D Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16199	Exhibit 5	McCurdy, Joel M.D. Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16200	Exhibit 6	McCurdy, Joel M.D. Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16201	Exhibit 7	McCurdy, Joel M.D. Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16202	Exhibit 8	McCurdy, Joel M.D. Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16203	Exhibit 9	McCurdy, Joel M.D. Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16204	Exhibit 1	McGuire, Jessica Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16205	Exhibit 2	McGuire, Jessica Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16206	Exhibit 3	McGuire, Jessica Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16207	Exhibit 4	McGuire, Jessica Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16208	Exhibit 5	McGuire, Jessica Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16209	Exhibit 1	Brown, Nare Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16210	Exhibit 1	Murphy, RobinExhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16211	Exhibit 2	Murphy, RobinExhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16212	Exhibit 3	Murphy, RobinExhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16213	Exhibit 4	Murphy, RobinExhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16214	Exhibit 5	Murphy, RobinExhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16215	Exhibit 6	Murphy, RobinExhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16216	Exhibit 7	Murphy, RobinExhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16217	Exhibit 8	Murphy, RobinExhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16218	Exhibit 1	Pfeifer, EricExhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16219	Exhibit 2	Pfeifer, EricExhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16220	Exhibit 3	Pfeifer, EricExhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16221	Exhibit 4	Pfeifer, EricExhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16222	Exhibit 5	Pfeifer, EricExhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16223	Exhibit 6	Pfeifer, EricExhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16224	Exhibit 7	Pfeifer, EricExhibit 7		
16225	Exhibit 8	Pfeifer, EricExhibit 8		
16226	Exhibit 9	Pfeifer, EricExhibit 9		
16227	Exhibit 10	Pfeifer, EricExhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16228	Exhibit 11	Pfeifer, EricExhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16229	Exhibit 1	Nguyen, ClaireExhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16230	Exhibit 2	Nguyen, ClaireExhibit 2		
16231	Exhibit 3	Nguyen, ClaireExhibit 3		
16232	Exhibit 4	Nguyen, ClaireExhibit 4		
16233	Exhibit 5	Nguyen, ClaireExhibit 5		
16234	Exhibit 6	Nguyen, ClaireExhibit 6		
16235	Exhibit 7	Nguyen, ClaireExhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16236	Exhibit 8	Nguyen, ClaireExhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16237	Exhibit 9	Nguyen, ClaireExhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
16238	Exhibit 10	Nguyen, Claire Exhibit 10	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16239	Exhibit 11	Nguyen, Claire Exhibit 11	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16240	Exhibit 12	Nguyen, Claire Exhibit 12	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16241	Exhibit 13	Nguyen, Claire Exhibit 13	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16242	Exhibit 14	Nguyen, Claire Exhibit 14	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16243	Exhibit 1	Barnhouse, Jenny Exhibit 1	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16244	Exhibit 2	Barnhouse, Jenny Exhibit 2	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16245	Exhibit 3	Barnhouse, Jenny Exhibit 3	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16246	Exhibit 4	Barnhouse, Jenny Exhibit 4	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16247	Exhibit 5	Barnhouse, Jenny Exhibit 5	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16248	Exhibit 6	Barnhouse, Jenny Exhibit 6	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
16249	Exhibit 7	Barnhouse, Jenny Exhibit 7	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16250	Exhibit 8	Barnhouse, Jenny Exhibit 8	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16251	Exhibit 9	Barnhouse, Jenny Exhibit 9	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16252	Exhibit 1	Vogt, (Robert) Don Exhibit 1	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16253	Exhibit 2	Vogt, (Robert) Don Exhibit 2	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16254	Exhibit 3	Vogt, (Robert) Don Exhibit 3	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16255	Exhibit 4	Vogt, (Robert) Don Exhibit 4	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16256	Exhibit 5	Vogt, (Robert) Don Exhibit 5	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16257	Exhibit 6	Vogt, (Robert) Don Exhibit 6	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16258	Exhibit 7	Vogt, (Robert) Don Exhibit 7	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16259	Exhibit 8	Vogt, (Robert) Don Exhibit 8	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16260	Exhibit 9	Veet, (Robert) Don; Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16261	Exhibit 1	Stewart, Mark Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16262	Exhibit 2	Stewart, Mark Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16263	Exhibit 3	Stewart, Mark Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16264	Exhibit 4	Stewart, Mark Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16265	Exhibit 5	Stewart, Mark Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16266	Exhibit 6	Stewart, Mark Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16267	Exhibit 7	Stewart, Mark Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16268	Exhibit 8	Stewart, Mark Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16269	Exhibit 9	Stewart, Mark Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16270	Exhibit 10	Stewart, Mark Exhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16271	Exhibit 11	Stewart, Mark Exhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16272	Exhibit 12	Stewart, Mark Exhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16273	Exhibit 13	Stewart, Mark Exhibit 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16274	Exhibit 14	Stewart, Mark Exhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16275	Exhibit 15	Stewart, Mark Exhibit 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16276	Exhibit 16	Stewart, Mark Exhibit 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16277	Exhibit 17	Stewart, Mark Exhibit 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16278	Exhibit 18	Stewart, Mark Exhibit 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16279	Exhibit 19	Stewart, Mark Exhibit 19	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16280	Exhibit 20	Stewart, Mark Exhibit 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16281	Exhibit 21	Stewart, Mark Exhibit 21	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16282	Exhibit 22	Stewart, Mark Exhibit 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16283	Exhibit 23	Stewart, Mark Exhibit 23	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16284	Exhibit 24	Stewart, Mark Exhibit 24	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16285	Exhibit 25	Stewart, Mark Exhibit 25	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16286	Exhibit 26	Stewart, Mark Exhibit 26	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16287	Exhibit 27	Stewart, Mark Exhibit 27	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16288	Exhibit 28	Stewart, Mark Exhibit 28	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16289	Exhibit 1	Herdon, Michael Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16290	Exhibit 2	Herdon, Michael Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16291	Exhibit 3	Herdon, Michael Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16292	Exhibit 4	Herdon, Michael Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16293	Exhibit 5	Herdon, Michael Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16294	Exhibit 6	Herdon, Michael/Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16295	Exhibit 7	Herdon, Michael/Exhibit 7		
16296	Exhibit 8	Herdon, Michael/Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16297	Exhibit 9	Herdon, Michael/Exhibit 9		
16298	Exhibit 10	Herdon, Michael/Exhibit 10		
16299	Exhibit 11	Herdon, Michael/Exhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16300	Exhibit 12	Herdon, Michael/Exhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16301	Exhibit 13	Herdon, Michael/Exhibit 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16302	Exhibit 14	Herdon, Michael/Exhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16303	Exhibit 15	Herdon, Michael/Exhibit 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16304	Exhibit 16	Herdon, Michael/Exhibit 16		
16305	Exhibit 17	Herdon, Michael/Exhibit 17		
16306	Exhibit 1	Holderread, Bethany/Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16307	Exhibit 2	Holderread, Bethany/Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16308	Exhibit 3	Holderread, Bethany/Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16309	Exhibit 4	Holderread, Bethany Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16310	Exhibit 5	Holderread, Bethany Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16311	Exhibit 6	Holderread, Bethany Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16312	Exhibit 7	Holderread, Bethany Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16313	Exhibit 1	Beasley, Burl G. (DPP) Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16314	Exhibit 2	Beasley, Burl G. (DPP) Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16315	Exhibit 3	Beasley, Burl G. (DPP) Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16316	Exhibit 4	Beasley, Burl G. (DPP) Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16317	Exhibit 5	Beasley, Burl G. (DPP) Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16318	Exhibit 6	Beasley, Burl G. (DPP) Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16319	Exhibit 7	Beasley, Burl G. (DPP) Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16320	Exhibit 8	Beasley, Burl G. (DPH)Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16321	Exhibit 9	Beasley, Burl G. (DPH)Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16322	Exhibit 10	Beasley, Burl G. (DPH)Exhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16323	Exhibit 11	Beasley, Burl G. (DPH)Exhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16324	Exhibit 12	Beasley, Burl G. (DPH)Exhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16325	Exhibit 13	Beasley, Burl G. (DPH)Exhibit 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16326	Exhibit 14	Beasley, Burl G. (DPH)Exhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16327	Exhibit 15	Beasley, Burl G. (DPH)Exhibit 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16328	Exhibit 16	Beasley, Burl G. (DPH)Exhibit 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16329	Exhibit 17	Beasley, Burl G. (DPH)Exhibit 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16330	Exhibit 18	Beasley, Burl G. (DPH)Exhibit 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16331	Exhibit 19	Beasley, Burl G. (DPh)Exhibit 19	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16332	Exhibit 20	Beasley, Burl G. (DPh)Exhibit 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16333	Exhibit 21	Beasley, Burl G. (DPh)Exhibit 21		
16334	Exhibit 22	Beasley, Burl G. (DPh)Exhibit 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16335	Exhibit 1	Beasley, Burl G. (DPh)Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16336	Exhibit 2	Beasley, Burl G. (DPh)Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16337	Exhibit 3	Beasley, Burl G. (DPh)Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16338	Exhibit 4	Beasley, Burl G. (DPh)Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16339	Exhibit 5	Beasley, Burl G. (DPh)Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16340	Exhibit 6	Beasley, Burl G. (DPh)Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16341	Exhibit 7	Beasley, Burl G. (DPh)Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16342	Exhibit 8	Beasley, Burl G. (DPh)Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16343	Exhibit 9	Beasley, Burl G. (DPh)Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
16344	Exhibit 10	Beasley, Burl G. (DPh)Exhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
16345	Exhibit 11	Beasley, Burl G. (DPh)Exhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
16346	Exhibit 12	Beasley, Burl G. (DPh)Exhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
16347	Exhibit 13	Beasley, Burl G. (DPh)Exhibit 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
16348	Exhibit 14	Beasley, Burl G. (DPh)Exhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
16349	Exhibit 15	Beasley, Burl G. (DPh)Exhibit 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
16350	Exhibit 16	Beasley, Burl G. (DPh)Exhibit 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
16351	Exhibit 17	Beasley, Burl G. (DPh)Exhibit 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
16352	Exhibit 18	Beasley, Burl G. (DPh)Exhibit 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
16353	Exhibit 19	Beasley, Burl G. (DPh)Exhibit 19	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16354	Exhibit 20	Beasley, Burl G. (DPH)Exhibit 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16355	Exhibit 21	Beasley, Burl G. (DPH)Exhibit 21	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16356	Exhibit 22	Beasley, Burl G. (DPH)Exhibit 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16357	Exhibit 23	Beasley, Burl G. (DPH)Exhibit 23	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16358	Exhibit 24	Beasley, Burl G. (DPH)Exhibit 24	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16359	Exhibit 25	Beasley, Burl G. (DPH)Exhibit 25	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16360	Exhibit 1	Keast, ShellieExhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16361	Exhibit 2	Keast, ShellieExhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16362	Exhibit 3	Keast, ShellieExhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16363	Exhibit 4	Keast, ShellieExhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16364	Exhibit 5	Keast, ShellieExhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
16365	Exhibit 6	Keast, Shellie; Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16366	Exhibit 7	Keast, Shellie; Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16367	Exhibit 8	Keast, Shellie; Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16368	Exhibit 9	Keast, Shellie; Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16369	Exhibit 10	Keast, Shellie; Exhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16370	Exhibit 11	Keast, Shellie; Exhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16371	Exhibit 12	Keast, Shellie; Exhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16372	Exhibit 13	Keast, Shellie; Exhibit 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16373	Exhibit 14	Keast, Shellie; Exhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16374	Exhibit 15	Keast, Shellie; Exhibit 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16375	Exhibit 16	Keast, Shellie; Exhibit 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
16376	Exhibit 17	Keast, ShellieExhibit 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16377	Exhibit 18	Keast, ShellieExhibit 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16378	Exhibit 19	Keast, ShellieExhibit 19	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16379	Exhibit 20	Keast, ShellieExhibit 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16380	Exhibit 21	Keast, ShellieExhibit 21	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16381	Exhibit 22	Keast, ShellieExhibit 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16382	Exhibit 23	Keast, ShellieExhibit 23	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16383	Exhibit 24	Keast, ShellieExhibit 24	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16384	Exhibit 25	Keast, ShellieExhibit 25		
16385	Exhibit 26	Keast, ShellieExhibit 26		
16386	Exhibit 27	Keast, ShellieExhibit 27		
16387	Exhibit 1	Woodward, MarkExhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16388	Exhibit 2	Woodward, MarkExhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16389	Exhibit 3	Woodward, Mark; Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16390	Exhibit 4	Woodward, Mark; Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16391	Exhibit 5	Woodward, Mark; Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16392	Exhibit 6	Woodward, Mark; Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16393	Exhibit 7	Woodward, Mark; Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16394	Exhibit 8	Woodward, Mark; Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16395	Exhibit 9	Woodward, Mark; Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16396	Exhibit 10	Woodward, Mark; Exhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16397	Exhibit 11	Woodward, Mark; Exhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16398	Exhibit 12	Woodward, Mark; Exhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16399	Exhibit 13	Woodward, Mark; Exhibit 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16400	Exhibit 1	Crawford, Steven Alan (MD)Exhibit 1	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16401	Exhibit 2	Crawford, Steven Alan (MD)Exhibit 2	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16402	Exhibit 3	Crawford, Steven Alan (MD)Exhibit 3	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16403	Exhibit 4	Crawford, Steven Alan (MD)Exhibit 4	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16404	Exhibit 5	Crawford, Steven Alan (MD)Exhibit 5	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16405	Exhibit 6	Crawford, Steven Alan (MD)Exhibit 6	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16406	Exhibit 7	Crawford, Steven Alan (MD)Exhibit 7	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16407	Exhibit 8	Crawford, Steven Alan (MD)Exhibit 8	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16408	Exhibit 9	Crawford, Steven Alan (MD)Exhibit 9	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16409	Exhibit 10	Crawford, Steven Alan (MD)Exhibit 10	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16410	Exhibit 11	Crawford, Steven Alan (MD)Exhibit 11	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16411	Exhibit 12	Crawford, Steven Alan (MD) Exhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16412	Exhibit 13	Crawford, Steven Alan (MD) Exhibit 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16413	Exhibit 14	Crawford, Steven Alan (MD) Exhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16414	Exhibit 15	Crawford, Steven Alan (MD) Exhibit 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16415	Exhibit 16	Crawford, Steven Alan (MD) Exhibit 16		
16416	Exhibit 17	Crawford, Steven Alan (MD) Exhibit 17		
16417	Exhibit 18	Crawford, Steven Alan (MD) Exhibit 18		
16418	Exhibit 19	Crawford, Steven Alan (MD) Exhibit 19		
16419	Exhibit 20	Crawford, Steven Alan (MD) Exhibit 20		
16420	Exhibit 21	Crawford, Steven Alan (MD) Exhibit 21		
16421	Exhibit 22	Crawford, Steven Alan (MD) Exhibit 22		
16422	Exhibit 23	Crawford, Steven Alan (MD) Exhibit 23		
16423	Exhibit 24	Crawford, Steven Alan (MD) Exhibit 24		
16424	Exhibit 25	Crawford, Steven Alan (MD) Exhibit 25		
16425	Exhibit 26	Crawford, Steven Alan (MD) Exhibit 26		
16426	Exhibit 27	Crawford, Steven Alan (MD) Exhibit 27		
16427	Exhibit 1	Bruce, Deborah Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16428	Exhibit 2	Bruce, Deborah Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16429	Exhibit 3	Bruce, Deborah Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16430	Exhibit 4	Bruce, Deborah Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16431	Exhibit 5	Bruce, DeborahExhibit 5	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16432	Exhibit 6	Bruce, DeborahExhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16433	Exhibit 7	Bruce, DeborahExhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16434	Exhibit 8	Bruce, DeborahExhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16435	Exhibit 9	Bruce, DeborahExhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16436	Exhibit 10	Bruce, DeborahExhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16437	Exhibit 11	Bruce, DeborahExhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16438	Exhibit 12	Bruce, DeborahExhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16439	Exhibit 13	Bruce, DeborahExhibit 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16440	Exhibit 14	Bruce, DeborahExhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16441	Exhibit 15	Bruce, DeborahExhibit 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16442	Exhibit 16	Bruce, DeborahExhibit 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16443	Exhibit 17	Bruce, DeborahExhibit 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16444	Exhibit 18	Bruce, DeborahExhibit 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16445	Exhibit 1	Hamilton-Fain, CindyExhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16446	Exhibit 2	Hamilton-Fain, CindyExhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16447	Exhibit 3	Hamilton-Fain, CindyExhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16448	Exhibit 4	Hamilton-Fain, CindyExhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16449	Exhibit 5	Hamilton-Fain, CindyExhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16450	Exhibit 6	Hamilton-Fain, CindyExhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16451	Exhibit 7	Hamilton-Fain, CindyExhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16452	Exhibit 8	Hamilton-Fain, CindyExhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16453	Exhibit 9	Hamilton-Fain, Cindy Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16454	Exhibit 10	Hamilton-Fain, Cindy Exhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16455	Exhibit 11	Hamilton-Fain, Cindy Exhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16456	Exhibit 12	Hamilton-Fain, Cindy Exhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16457	Exhibit 13	Hamilton-Fain, Cindy Exhibit 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16458	Exhibit 14	Hamilton-Fain, Cindy Exhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16459	Exhibit 15	Hamilton-Fain, Cindy Exhibit 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16460	Exhibit 16	Hamilton-Fain, Cindy Exhibit 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16461	Exhibit 17	Hamilton-Fain, Cindy Exhibit 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16462	Exhibit 1	Lawler, Frank Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16463	Exhibit 2	Lawler, Frank Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16464	Exhibit 3	Lawler, Frank Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16465	Exhibit 4	Lawler, Frank Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16466	Exhibit 5	Lawler, Frank Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16467	Exhibit 6	Lawler, Frank Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16468	Exhibit 7	Lawler, Frank Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16469	Exhibit 8	Lawler, Frank Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16470	Exhibit 1	Rodgers, Susan Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16471	Exhibit 2	Rodgers, Susan Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16472	Exhibit 3	Rodgers, Susan Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16473	Exhibit 4	Rodgers, Susan Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16474	Exhibit 5	Rodgers, Susan Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16475	Exhibit 1	Griffith, Ty Exhibit 1		

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
16476	Exhibit 2	Griffith, TyExhibit 2	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16477	Exhibit 3	Griffith, TyExhibit 3	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16478	Exhibit 4	Griffith, TyExhibit 4	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16479	Exhibit 5	Griffith, TyExhibit 5	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16480	Exhibit 6	Griffith, TyExhibit 6		
16481	Exhibit 7	Griffith, TyExhibit 7		
16482	Exhibit 8	Griffith, TyExhibit 8		
16483	Exhibit 1	Herdon, MichaelExhibit 1	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16484	Exhibit 2	Herdon, MichaelExhibit 2	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16485	Exhibit 3	Herdon, MichaelExhibit 3	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16486	Exhibit 4	Herdon, MichaelExhibit 4	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16487	Exhibit 5	Herdon, MichaelExhibit 5	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16488	Exhibit 6	Herdon, MichaelExhibit 6	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16489	Exhibit 7	Herdon, MichaelExhibit 7	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16490	Exhibit 8	Herdon, MichaelExhibit 8	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tewa exhibit because J&J and Janssen have not had the opportunity to review them)
16491	Exhibit 9	Herdon, Michael/Exhibit 9		
16492	Exhibit 10	Herdon, Michael/Exhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16493	Exhibit 11	Herdon, Michael/Exhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16494	Exhibit 1	Pastermik-Ikard, Becky (JD, RN, MSN)/Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16495	Exhibit 2	Pastermik-Ikard, Becky (JD, RN, MSN)/Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16496	Exhibit 3	Pastermik-Ikard, Becky (JD, RN, MSN)/Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16497	Exhibit 4	Pastermik-Ikard, Becky (JD, RN, MSN)/Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16498	Exhibit 5	Pastermik-Ikard, Becky (JD, RN, MSN)/Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16499	Exhibit 6	Pastermik-Ikard, Becky (JD, RN, MSN)/Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16500	Exhibit 7	Pastermik-Ikard, Becky (JD, RN, MSN)/Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16501	Exhibit 8	Pastermik-Ikard, Becky (JD, RN, MSN)/Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16502	Exhibit 1	Van Zee, Art/Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16503	Exhibit 2	Van Zee, ArtExhibit 2	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16504	Exhibit 3	Van Zee, ArtExhibit 3	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16505	Exhibit 4	Van Zee, ArtExhibit 4	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16506	Exhibit 5	Van Zee, ArtExhibit 5	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16507	Exhibit 6	Van Zee, ArtExhibit 6	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16508	Exhibit 7	Van Zee, ArtExhibit 7	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16509	Exhibit 8	Van Zee, ArtExhibit 8	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16510	Exhibit 9	Van Zee, ArtExhibit 9	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16511	Exhibit 10	Van Zee, ArtExhibit 10	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16512	Exhibit 11	Van Zee, ArtExhibit 11	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16513	Exhibit 12	Van Zee, ArtExhibit 12	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	Stare's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16514	Exhibit 1	Varghese, ReJ Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16515	Exhibit 2	Varghese, ReJ Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16516	Exhibit 3	Varghese, ReJ Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16517	Exhibit 4	Varghese, ReJ Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16518	Exhibit 5	Varghese, ReJ Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16519	Exhibit 6	Varghese, ReJ Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16520	Exhibit 1	Cottrian, Terry (PhD) Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16521	Exhibit 2	Cottrian, Terry (PhD) Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16522	Exhibit 3	Cottrian, Terry (PhD) Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16523	Exhibit 4	Cottrian, Terry (PhD) Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16524	Exhibit 5	Cottrian, Terry (PhD) Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16525	Exhibit 6	Cottrhan, Terry (PhD) Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16526	Exhibit 7	Cottrhan, Terry (PhD) Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16527	Exhibit 8	Cottrhan, Terry (PhD) Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16528	Exhibit 9	Cottrhan, Terry (PhD) Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16529	Exhibit 1	Curtis, Byron Ph.D., F-ABFT Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16530	Exhibit 2	Curtis, Byron Ph.D., F-ABFT Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16531	Exhibit 3	Curtis, Byron Ph.D., F-ABFT Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16532	Exhibit 4	Curtis, Byron Ph.D., F-ABFT Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16533	Exhibit 5	Curtis, Byron Ph.D., F-ABFT Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16534	Exhibit 6	Curtis, Byron Ph.D., F-ABFT Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16535	Exhibit 7	Curtis, Byron Ph.D., F-ABFT Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16536	Exhibit 8	Curtis, Byron Ph.D., F-ABFTExhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16537	Exhibit 9	Curtis, Byron Ph.D., F-ABFTExhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16538	Exhibit 10	Curtis, Byron Ph.D., F-ABFTExhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16539	Exhibit 11	Curtis, Byron Ph.D., F-ABFTExhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16540	Exhibit 16	Beasley, Burl G. (DPh)Exhibit 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16541	Exhibit 18	Beasley, Burl G. (DPh)Exhibit 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16542	Exhibit 24	Beasley, Burl G. (DPh)Exhibit 24	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16543	Exhibit 24	Beasley, Burl G. (DPh)Exhibit 24	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16544	Exhibit 26	Beasley, Burl G. (DPh)Exhibit 26	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16545	Exhibit 27	Beasley, Burl G. (DPh)Exhibit 27	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16546	Exhibit 28	Beasley, Burl G. (DPh)Exhibit 28	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16547	Exhibit 29	Beasley, Burl G. (DPh)Exhibit 29	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16548	Exhibit 30	Beasley, Burl G. (DPh)Exhibit 30	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16549	Exhibit 31	Beasley, Burl G. (DPh)Exhibit 31	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16550	Exhibit 32	Beasley, Burl G. (DPh)Exhibit 32	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16551	Exhibit 33	Beasley, Burl G. (DPh)Exhibit 33	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16552	Exhibit 34	Beasley, Burl G. (DPh)Exhibit 34	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16553	Exhibit 35	Beasley, Burl G. (DPh)Exhibit 35	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16554	Exhibit 36	Beasley, Burl G. (DPh)Exhibit 36	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16555	Exhibit 37	Beasley, Burl G. (DPh)Exhibit 37	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16556	Exhibit 38	Beasley, Burl G. (DPh)Exhibit 38	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16557	Exhibit 39	Beasley, Burl G. (DPh)Exhibit 39	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16558	Exhibit 40	Beasley, Burl G. (DPh)Exhibit 40		

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16559	Exhibit 41	Beasley, Burl G. (DDP)Exhibit 41	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16560	Exhibit 42	Beasley, Burl G. (DDP)Exhibit 42	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16561	Exhibit 43	Beasley, Burl G. (DDP)Exhibit 43	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16562	Exhibit 44	Beasley, Burl G. (DDP)Exhibit 44	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16563	Exhibit 45	Beasley, Burl G. (DDP)Exhibit 45	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16564	Exhibit 46	Beasley, Burl G. (DDP)Exhibit 46	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16565	Exhibit 47	Beasley, Burl G. (DDP)Exhibit 47		
16566	Exhibit 48	Beasley, Burl G. (DDP)Exhibit 48		
16567	Exhibit 1	Gerszewski, AlexExhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16568	Exhibit 2	Gerszewski, AlexExhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16569	Exhibit 3	Gerszewski, AlexExhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16570	Exhibit 4	Gerszewski, AlexExhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16571	Exhibit 1	Tate, TravisExhibit 1		

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16572	Exhibit 2	Tate, TravisExhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16573	Exhibit 3	Tate, TravisExhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16574	Exhibit 4	Tate, TravisExhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16575	Exhibit 5	Tate, TravisExhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16576	Exhibit 6	Tate, TravisExhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16577	Exhibit 7	Tate, TravisExhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16578	Exhibit 8	Tate, TravisExhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16579	Exhibit 9	Tate, TravisExhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16580	Exhibit 10	Tate, TravisExhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16581	Exhibit 11	Tate, TravisExhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16582	Exhibit 1	Egedal, Karen, D.Ph. Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16583	Exhibit 2	Egedsal, Karen, D.Ph.Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16584	Exhibit 3	Egedsal, Karen, D.Ph.Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16585	Exhibit 4	Egedsal, Karen, D.Ph.Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16586	Exhibit 5	Egedsal, Karen, D.Ph.Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16587	Exhibit 6	Egedsal, Karen, D.Ph.Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16588	Exhibit 7	Egedsal, Karen, D.Ph.Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16589	Exhibit 8	Egedsal, Karen, D.Ph.Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16590	Exhibit 9	Egedsal, Karen, D.Ph.Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16591	Exhibit 10	Egedsal, Karen, D.Ph.Exhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16592	Exhibit 11	Egedsal, Karen, D.Ph.Exhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16593	Exhibit 12	Egedsal, Karen, D.Ph.Exhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16594	Exhibit 13	Egesdal, Karen, D.Ph. Exhibit 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16595	Exhibit 14	Egesdal, Karen, D.Ph. Exhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16596	Exhibit 15	Egesdal, Karen, D.Ph. Exhibit 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16597	Exhibit 16	Egesdal, Karen, D.Ph. Exhibit 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16598	Exhibit 17	Egesdal, Karen, D.Ph. Exhibit 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16599	Exhibit 18	Egesdal, Karen, D.Ph. Exhibit 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16600	Exhibit 19	Egesdal, Karen, D.Ph. Exhibit 19	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16601	Exhibit 20	Egesdal, Karen, D.Ph. Exhibit 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16602	Exhibit 21	Egesdal, Karen, D.Ph. Exhibit 21	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16603	Exhibit 22	Egesdal, Karen, D.Ph. Exhibit 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16604	Exhibit 23	Egesdal, Karen, D.Ph. Exhibit 23	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16605	Exhibit 24	Egesdal, Karen, D.Ph. Exhibit 24	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16606	Exhibit 25	Egesdal, Karen, D.Ph. Exhibit 25	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16607	Exhibit 26	Egesdal, Karen, D.Ph. Exhibit 26	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16608	Exhibit 27	Egesdal, Karen, D.Ph. Exhibit 27	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16609	Exhibit 28	Egesdal, Karen, D.Ph. Exhibit 28	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16610	Exhibit 1	Fugh-Berman, Adriane Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16611	Exhibit 2	Fugh-Berman, Adriane Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16612	Exhibit 3	Fugh-Berman, Adriane Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16613	Exhibit 4	Fugh-Berman, Adriane Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16614	Exhibit 5	Fugh-Berman, Adriane Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16615	Exhibit 6	Fugh-Berman, Adriane Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16616	Exhibit 7	Fugh-Berman, Adriane Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16617	Exhibit 8	Fugh-Berman, Adriane Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16618	Exhibit 9	Fugh-Berman, Adriane Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16619	Exhibit 10	Fugh-Berman, AdrianeExhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16620	Exhibit 11	Fugh-Berman, AdrianeExhibit 11		
16621	Exhibit 12	Fugh-Berman, AdrianeExhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16622	Exhibit 13	Fugh-Berman, AdrianeExhibit 13		
16623	Exhibit 14	Fugh-Berman, AdrianeExhibit 14		
16624	Exhibit 15	Fugh-Berman, AdrianeExhibit 15		
16625	Exhibit 16	Fugh-Berman, AdrianeExhibit 16		
16626	Exhibit 17	Fugh-Berman, AdrianeExhibit 17		
16627	Exhibit 18	Fugh-Berman, AdrianeExhibit 18		
16628	Exhibit 19	Fugh-Berman, AdrianeExhibit 19		
16629	Exhibit 20	Fugh-Berman, AdrianeExhibit 20		
16630	Exhibit 21	Fugh-Berman, AdrianeExhibit 21		
16631	Exhibit 22	Fugh-Berman, AdrianeExhibit 22		
16632	Exhibit 23	Fugh-Berman, AdrianeExhibit 23		
16633	Exhibit 24	Fugh-Berman, AdrianeExhibit 24		
16634	Exhibit 25	Fugh-Berman, AdrianeExhibit 25		
16635	Exhibit 26	Fugh-Berman, AdrianeExhibit 26		
16636	Exhibit 27	Fugh-Berman, AdrianeExhibit 27		
16637	Exhibit 28	Fugh-Berman, AdrianeExhibit 28		
16638	Exhibit 29	Fugh-Berman, AdrianeExhibit 29		
16639	Exhibit 30	Fugh-Berman, AdrianeExhibit 30		
16640	Exhibit 31	Fugh-Berman, AdrianeExhibit 31		
16641	Exhibit 32	Fugh-Berman, AdrianeExhibit 32		
16642	Exhibit 33	Fugh-Berman, AdrianeExhibit 33		
16643	Exhibit 34	Fugh-Berman, AdrianeExhibit 34		
16644	Exhibit 35	Fugh-Berman, AdrianeExhibit 35		
16645	Exhibit 36	Fugh-Berman, AdrianeExhibit 36		
16646	Exhibit 37	Fugh-Berman, AdrianeExhibit 37		
16647	Exhibit 38	Fugh-Berman, AdrianeExhibit 38		
16648	Exhibit 39	Fugh-Berman, AdrianeExhibit 39		
16649	Exhibit 40	Fugh-Berman, AdrianeExhibit 40		
16650	Exhibit 41	Fugh-Berman, AdrianeExhibit 41		
16651	Exhibit 42	Fugh-Berman, AdrianeExhibit 42		
16652	Exhibit 43	Fugh-Berman, AdrianeExhibit 43		
16653	Exhibit 44	Fugh-Berman, AdrianeExhibit 44		
16654	Exhibit 45	Fugh-Berman, AdrianeExhibit 45		
16655	Exhibit 46	Fugh-Berman, AdrianeExhibit 46		
16656	Exhibit 47	Fugh-Berman, AdrianeExhibit 47		

Exhibit No.	Bates No.	Description	Sate's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16657	Exhibit 48	Fugh-Berman, AdrianeExhibit 48	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16658	Exhibit 43a	Fugh-Berman, AdrianeExhibit 43a	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16659	Exhibit 1	Hawkins, JessicacExhibit 1		
16660	Exhibit 2	Hawkins, JessicacExhibit 2		
16661	Exhibit 3	Hawkins, JessicacExhibit 3		
16662	Exhibit 4	Hawkins, JessicacExhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16663	Exhibit 1	Martin, SamExhibit 1		
16664	Exhibit 2	Martin, SamExhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16665	Exhibit 3	Martin, SamExhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16666	Exhibit 4	Martin, SamExhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16667	Exhibit 1	Wade, KerriExhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16668	Exhibit 2	Wade, KerriExhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16669	Exhibit 3	Wade, KerriExhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16670	Exhibit 4	Wade, KerriExhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16671	Exhibit 5	Wade, KerriExhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16672	Exhibit 6	Wade, KerrExhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16673	Exhibit 7	Wade, KerrExhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16674	Exhibit 8	Wade, KerrExhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16675	Exhibit 9	Wade, KerrExhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16676	Exhibit 10	Wade, KerrExhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16677	Exhibit 1	Hawkins, JessicaExhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16678	Exhibit 2	Hawkins, JessicaExhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16679	Exhibit 1	Kolodny, AndrewExhibit 1		
16680	Exhibit 2	Kolodny, AndrewExhibit 2		
16681	Exhibit 3	Kolodny, AndrewExhibit 3		
16682	Exhibit 4	Kolodny, AndrewExhibit 4		
16683	Exhibit 5	Kolodny, AndrewExhibit 5		
16684	Exhibit 6	Kolodny, AndrewExhibit 6		
16685	Exhibit 7	Kolodny, AndrewExhibit 7		
16686	Exhibit 8	Kolodny, AndrewExhibit 8		
16687	Exhibit 9	Kolodny, AndrewExhibit 9		
16688	Exhibit 10	Kolodny, AndrewExhibit 10		
16689	Exhibit 11	Kolodny, AndrewExhibit 11		
16690	Exhibit 12	Kolodny, AndrewExhibit 12		
16691	Exhibit 13	Kolodny, AndrewExhibit 13		
16692	Exhibit 14	Kolodny, AndrewExhibit 14		
16693	Exhibit 15	Kolodny, AndrewExhibit 15		
16694	Exhibit 16	Kolodny, AndrewExhibit 16		

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16695	Exhibit 17	Kolodny, Andrew Exhibit 17		
16696	Exhibit 18	Kolodny, Andrew Exhibit 18		
16697	Exhibit 19	Kolodny, Andrew Exhibit 19		
16698	Exhibit 20	Kolodny, Andrew Exhibit 20		
16699	Exhibit 21	Kolodny, Andrew Exhibit 21		
16700	Exhibit 22	Kolodny, Andrew Exhibit 22		
16701	Exhibit 1	Mazloomdoost, Danesh Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16702	Exhibit 2	Mazloomdoost, Danesh Exhibit 2		
16703	Exhibit 3	Mazloomdoost, Danesh Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16704	Exhibit 4	Mazloomdoost, Danesh Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16705	Exhibit 5	Mazloomdoost, Danesh Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16706	Exhibit 6	Mazloomdoost, Danesh Exhibit 6		
16707	Exhibit 7	Mazloomdoost, Danesh Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16708	Exhibit 8	Mazloomdoost, Danesh Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16709	Exhibit 9	Mazloomdoost, Danesh Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16710	Exhibit 10	Mazloomdoost, Danesh Exhibit 10		
16711	Exhibit 11	Mazloomdoost, Danesh Exhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16712	Exhibit 12	Mazloomdoost, Danesh Exhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16713	Exhibit 1a	Kolodny, AndrewExhibit 1a		
16714	Exhibit 23	Kolodny, AndrewExhibit 23		
16715	Exhibit 24	Kolodny, AndrewExhibit 24		
16716	Exhibit 25	Kolodny, AndrewExhibit 25		
16717	Exhibit 26	Kolodny, AndrewExhibit 26		
16718	Exhibit 27	Kolodny, AndrewExhibit 27		
16719	Exhibit 28	Kolodny, AndrewExhibit 28		
16720	Exhibit 29	Kolodny, AndrewExhibit 29		
16721	Exhibit 30	Kolodny, AndrewExhibit 30		
16722	Exhibit 31	Kolodny, AndrewExhibit 31		
16723	Exhibit 32	Kolodny, AndrewExhibit 32		
16724	Exhibit 33	Kolodny, AndrewExhibit 33		
16725	Exhibit 34	Kolodny, AndrewExhibit 34		
16726	Exhibit 35	Kolodny, AndrewExhibit 35		
16727	Exhibit 36	Kolodny, AndrewExhibit 36		
16728	Exhibit 37	Kolodny, AndrewExhibit 37		
16729	Exhibit 38	Kolodny, AndrewExhibit 38		
16730	Exhibit 39	Kolodny, AndrewExhibit 39		
16731	Exhibit 40	Kolodny, AndrewExhibit 40		
16732	Exhibit 41	Kolodny, AndrewExhibit 41		
16733	Exhibit 42	Kolodny, AndrewExhibit 42		
16734	Exhibit 43	Kolodny, AndrewExhibit 43		
16735	Exhibit 44	Kolodny, AndrewExhibit 44		
16736	Exhibit 1	Pohl, MeleExhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16737	Exhibit 2	Pohl, MeleExhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16738	Exhibit 3	Pohl, MeleExhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16739	Exhibit 4	Pohl, MeleExhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16740	Exhibit 1	Stanton-Hodges, CarrieExhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16741	Exhibit 2	Stanton-Hodges, CarrieExhibit 2		

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16742	Exhibit 3	Slaton-Hodges, Carrie Exhibit 3	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16743	Exhibit 4	Slaton-Hodges, Carrie Exhibit 4	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16744	Exhibit 5	Slaton-Hodges, Carrie Exhibit 5		
16745	Exhibit 1	Weaver, Darrell Exhibit 1		
16746	Exhibit 2	Weaver, Darrell Exhibit 2	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16747	Exhibit 3	Weaver, Darrell Exhibit 3	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16748	Exhibit 4	Weaver, Darrell Exhibit 4	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16749	Exhibit 5	Weaver, Darrell Exhibit 5	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16750	Exhibit 6	Weaver, Darrell Exhibit 6	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16751	Exhibit 7	Weaver, Darrell Exhibit 7	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16752	Exhibit 8	Weaver, Darrell Exhibit 8	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16753	Exhibit 9	Weaver, Darrell Exhibit 9	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16754	Exhibit 10	Weaver, Darrell Exhibit 10	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
16755	Exhibit 11	Weaver, DarrellExhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16756	Exhibit 12	Weaver, DarrellExhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16757	Exhibit 13	Weaver, DarrellExhibit 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16758	Exhibit 14	Weaver, DarrellExhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16759	Exhibit 15	Weaver, DarrellExhibit 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16760	Exhibit 16	Weaver, DarrellExhibit 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16761	Exhibit 17	Weaver, DarrellExhibit 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16762	Exhibit 18	Weaver, DarrellExhibit 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16763	Exhibit 19	Weaver, DarrellExhibit 19	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16764	Exhibit 20	Weaver, DarrellExhibit 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16765	Exhibit 21	Weaver, DarrellExhibit 21	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16766	Exhibit 22	Weaver, DarrelExhibit 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16767	Exhibit 23	Weaver, DarrelExhibit 23	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16768	Exhibit 24	Weaver, DarrelExhibit 24	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16769	Exhibit 25	Weaver, DarrelExhibit 25	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16770	Exhibit 26	Weaver, DarrelExhibit 26	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16771	Exhibit 27	Weaver, DarrelExhibit 27	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16772	Exhibit 28	Weaver, DarrelExhibit 28	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16773	Exhibit 29	Weaver, DarrelExhibit 29	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16774	Exhibit 30	Weaver, DarrelExhibit 30	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16775	Exhibit 31	Weaver, DarrelExhibit 31	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16776	Exhibit 1	Gibson, JamesExhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16777	Exhibit 2	Gibson, JamesExhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16778	Exhibit 3	Gibson, James Exhibit 3		
16779	Exhibit 4	Gibson, James Exhibit 4		
16780	Exhibit 1	Reynolds, Mark Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16781	Exhibit 2	Reynolds, Mark Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16782	Exhibit 3	Reynolds, Mark Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16783	Exhibit 4	Reynolds, Mark Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16784	Exhibit 5	Reynolds, Mark Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16785	Exhibit 6	Reynolds, Mark Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16786	Exhibit 7	Reynolds, Mark Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16787	Exhibit 8	Reynolds, Mark Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16788	Exhibit 9	Reynolds, Mark Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16789	Exhibit 10	Reynolds, Mark Exhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16790	Exhibit 11	Reynolds, MarkExhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16791	Exhibit 12	Reynolds, MarkExhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16792	Exhibit 13	Reynolds, MarkExhibit 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16793	Exhibit 14	Reynolds, MarkExhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16794	Exhibit 15	Reynolds, MarkExhibit 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16795	Exhibit 1	Tate, TravisExhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16796	Exhibit 2	Tate, TravisExhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16797	Exhibit 3	Tate, TravisExhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16798	Exhibit 4	Tate, TravisExhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16799	Exhibit 5	Tate, TravisExhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16800	Exhibit 6	Tate, TravisExhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16801	Exhibit 7	Tate, TravisExhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16802	Exhibit 8	Tate, Travis; Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16803	Exhibit 9	Tate, Travis; Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16804	Exhibit 10	Tate, Travis; Exhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16805	Exhibit 11	Tate, Travis; Exhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16806	Exhibit 1	Bates, Tom; Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16807	Exhibit 2	Bates, Tom; Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16808	Exhibit 3	Bates, Tom; Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16809	Exhibit 4	Bates, Tom; Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16810	Exhibit 5	Bates, Tom; Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16811	Exhibit 1	Edmisten, Melton; Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16812	Exhibit 2	Edmisten, Melton; Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16813	Exhibit 3	Edminsten, Melton/Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16814	Exhibit 4	Edminsten, Melton/Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16815	Exhibit 5	Edminsten, Melton/Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16816	Exhibit 6	Edminsten, Melton/Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16817	Exhibit 7	Edminsten, Melton/Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16818	Exhibit 5	Gibson, James/Exhibit 5		
16819	Exhibit 6	Gibson, James/Exhibit 6		
16820	Exhibit 1	Holderread, Bethany/Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16821	Exhibit 2	Holderread, Bethany/Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16822	Exhibit 3	Holderread, Bethany/Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16823	Exhibit 4	Holderread, Bethany/Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16824	Exhibit 5	Holderread, Bethany/Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16825	Exhibit 6	Holderread, Bethany/Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16826	Exhibit 7	Holderread, Bethany Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16827	Exhibit 1	Tate, Travis Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16828	Exhibit 1	Ratcliff, Tony Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16829	Exhibit 2	Ratcliff, Tony Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16830	Exhibit 3	Ratcliff, Tony Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16831	Exhibit 4	Ratcliff, Tony Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16832	Exhibit 1	Hoos, Kristi Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16833	Exhibit 1	Beaman, Jason Exhibit 1		
16834	Exhibit 2	Beaman, Jason Exhibit 2		
16835	Exhibit 3	Beaman, Jason Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16836	Exhibit 4	Beaman, Jason Exhibit 4		
16837	Exhibit 5	Beaman, Jason Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16838	Exhibit 6	Beaman, Jason Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16839	Exhibit 7	Beaman, Jason; Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16840	Exhibit 8	Beaman, Jason; Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16841	Exhibit 9	Beaman, Jason; Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16842	Exhibit 10	Beaman, Jason; Exhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16843	Exhibit 11	Beaman, Jason; Exhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16844	Exhibit 12	Beaman, Jason; Exhibit 12	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403;	
16845	Exhibit 13	Beaman, Jason; Exhibit 13	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403;	
16846	Exhibit 14	Beaman, Jason; Exhibit 14	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403;	
16847	Exhibit 1	Herridon, Michael; Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16848	Exhibit 2	Herridon, Michael; Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16849	Exhibit 16	Beaman, Jason; Exhibit 16	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403;	
16850	Exhibit 17	Beaman, Jason; Exhibit 17	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403;	
16851	Exhibit 18	Beaman, Jason; Exhibit 18	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403;	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16852	Exhibit 19	Beaman, JasonExhibit 19	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16853	Exhibit 20	Beaman, JasonExhibit 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16854	Exhibit 21	Beaman, JasonExhibit 21	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16855	Exhibit 22	Beaman, JasonExhibit 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16856	Exhibit 1	Box, CraigExhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16857	Exhibit 2	Box, CraigExhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16858	Exhibit 3	Box, CraigExhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16859	Exhibit 4	Box, CraigExhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16860	Exhibit 5	Box, CraigExhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16861	Exhibit 6	Box, CraigExhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16862	Exhibit 7	Box, CraigExhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Pates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16863	Exhibit 1	McGregor, John Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16864	Exhibit 2	McGregor, John Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16865	Exhibit 1	Stone, Renzi Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16866	Exhibit 2	Stone, Renzi Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16867	Exhibit 3	Stone, Renzi Exhibit 3		
16868	Exhibit 4	Stone, Renzi Exhibit 4		
16869	Exhibit 1	Hawkins, Jessica Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16870	Exhibit 2	Hawkins, Jessica Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16871	Exhibit 3	Hawkins, Jessica Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16872	Exhibit 4	Hawkins, Jessica Exhibit 4		
16873	Exhibit 5	Hawkins, Jessica Exhibit 5		
16874	Exhibit 6	Hawkins, Jessica Exhibit 6		
16875	Exhibit 7	Hawkins, Jessica Exhibit 7		
16876	Exhibit 8	Hawkins, Jessica Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16877	Exhibit 9	Hawkins, Jessica Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16878	Exhibit 10	Hawkins, Jessica Exhibit 10		
16879	Exhibit 11	Hawkins, Jessica Exhibit 11		
16880	Exhibit 12	Hawkins, Jessica Exhibit 12		
16881	Exhibit 13	Hawkins, Jessica Exhibit 13		
16882	Exhibit 14	Hawkins, Jessica Exhibit 14		

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16883	Exhibit 15	Hawkins, Jessica; Exhibit 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16884	Exhibit 16	Hawkins, Jessica; Exhibit 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16885	Exhibit 17	Hawkins, Jessica; Exhibit 17		
16886	Exhibit 18	Hawkins, Jessica; Exhibit 18		
16887	Exhibit 19	Hawkins, Jessica; Exhibit 19		
16888	Exhibit 20	Hawkins, Jessica; Exhibit 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16889	Exhibit 21	Hawkins, Jessica; Exhibit 21	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16890	Exhibit 22	Hawkins, Jessica; Exhibit 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16891	Exhibit 23	Hawkins, Jessica; Exhibit 23	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16892	Exhibit 24	Hawkins, Jessica; Exhibit 24	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16893	Exhibit 25	Hawkins, Jessica; Exhibit 25	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16894	Exhibit 26	Hawkins, Jessica; Exhibit 26	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16895	Exhibit 27	Hawkins, Jessica; Exhibit 27	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16896	Exhibit 28	Hawkins, Jessica; Exhibit 28		

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16897	Exhibit 29	Hawkins, JessicaExhibit 29	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16898	Exhibit 30	Hawkins, JessicaExhibit 30	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16899	Exhibit 31	Hawkins, JessicaExhibit 31	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16900	Exhibit 32	Hawkins, JessicaExhibit 32	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16901	Exhibit 33	Hawkins, JessicaExhibit 33	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16902	Exhibit 34	Hawkins, JessicaExhibit 34	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16903	Exhibit 35	Hawkins, JessicaExhibit 35		
16904	Exhibit 36	Hawkins, JessicaExhibit 36		
16905	Exhibit 1	Krebs, ErinExhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16906	Exhibit 2	Krebs, ErinExhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16907	Exhibit 3	Krebs, ErinExhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16908	Exhibit 4	Krebs, ErinExhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16909	Exhibit 5	Krebs, ErneExhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16910	Exhibit 6	Krebs, ErneExhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16911	Exhibit 7	Krebs, ErneExhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16912	Exhibit 8	Krebs, ErneExhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16913	Exhibit 9	Krebs, ErneExhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16914	Exhibit 10	Krebs, ErneExhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16915	Exhibit 11	Krebs, ErneExhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16916	Exhibit 12	Krebs, ErneExhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16917	Exhibit 13	Krebs, ErneExhibit 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16918	Exhibit 14	Krebs, ErneExhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16919	Exhibit 1	McAllister, BillExhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tewa exhibit because J&J and Janssen have not had the opportunity to review them)
16920	Exhibit 2	McAllister, Bill; Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16921	Exhibit 3	McAllister, Bill; Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16922	Exhibit 4	McAllister, Bill; Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16923	Exhibit 5	McAllister, Bill; Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16924	Exhibit 1	Mendell, Gary; Exhibit 1		
16925	Exhibit 2	Mendell, Gary; Exhibit 2		
16926	Exhibit 3	Mendell, Gary; Exhibit 3		
16927	Exhibit 4	Mendell, Gary; Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16928	Exhibit 5	Mendell, Gary; Exhibit 5		
16929	Exhibit 6	Mendell, Gary; Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16930	Exhibit 1	Courtwright, David; Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16931	Exhibit 2	Courtwright, David; Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16932	Exhibit 3	Courtwright, David; Exhibit 3		
16933	Exhibit 4	Courtwright, David; Exhibit 4		
16934	Exhibit 5	Courtwright, David; Exhibit 5		
16935	Exhibit 1	Nguyen, Claire; Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16936	Exhibit 2	Nguyen, Claire; Exhibit 2		

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16937	Exhibit 3	Nguyen, Claire; Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16938	Exhibit 4	Nguyen, Claire; Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16939	Exhibit 5	Nguyen, Claire; Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16940	Exhibit 6	Nguyen, Claire; Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16941	Exhibit 7	Nguyen, Claire; Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16942	Exhibit 8	Nguyen, Claire; Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16943	Exhibit 9	Nguyen, Claire; Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16944	Exhibit 10	Nguyen, Claire; Exhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16945	Exhibit 11	Nguyen, Claire; Exhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16946	Exhibit 12	Nguyen, Claire; Exhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16947	Exhibit 13	Nguyen, Claire; Exhibit 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16948	Exhibit 14	Nguyen, Claire; Exhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16949	Exhibit 1	Clauw, Danielle; Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16950	Exhibit 2	Clauw, Danielle Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16951	Exhibit 3	Clauw, Danielle Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16952	Exhibit 4	Clauw, Danielle Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16953	Exhibit 5	Clauw, Danielle Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16954	Exhibit 6	Clauw, Danielle Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16955	Exhibit 7	Clauw, Danielle Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16956	Exhibit 8	Clauw, Danielle Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16957	Exhibit 9	Clauw, Danielle Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16958	Exhibit 1	Beaman, Jason Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16959	Exhibit 2	Beaman, Jason Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16960	Exhibit 3	Beaman, Jason Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16961	Exhibit 4	Beaman, Jason Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16962	Exhibit 5	Beaman, Jason Exhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16963	Exhibit 6	Beaman, Jason Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16964	Exhibit 7	Beaman, Jason Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16965	Exhibit 8	Beaman, Jason Exhibit 8	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403.	
16966	Exhibit 9	Beaman, Jason Exhibit 9	Confusion/prejudice, 12 O.S. § 2403.	
16967	Exhibit 10	Beaman, Jason Exhibit 10	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403.	
16968	Exhibit 11	Beaman, Jason Exhibit 11	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403.	
16969	Exhibit 12	Beaman, Jason Exhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16970	Exhibit 13	Beaman, Jason Exhibit 13	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403.	
16971	Exhibit 14	Beaman, Jason Exhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16972	Exhibit 15	Beaman, Jason Exhibit 15	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403.	
16973	Exhibit 16	Beaman, Jason Exhibit 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16974	Exhibit 17	Beaman, Jason Exhibit 17	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403.	
16975	Exhibit 18	Beaman, Jason Exhibit 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16976	Exhibit 19	Beaman, Jason Exhibit 19	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403.	
16977	Exhibit 20	Beaman, Jason Exhibit 20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16978	Exhibit 21	Beaman, Jason Exhibit 21	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
16979	Exhibit 22	Beaman, Jason Exhibit 22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16980	Exhibit 23	Beaman, Jason Exhibit 23	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16981	Exhibit 24	Beaman, Jason Exhibit 24	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16982	Exhibit 25	Beaman, Jason Exhibit 25	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16983	Exhibit 26	Beaman, Jason Exhibit 26	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16984	Exhibit 27	Beaman, Jason Exhibit 27	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16985	Exhibit 28	Beaman, Jason Exhibit 28	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16986	Exhibit 29	Beaman, Jason Exhibit 29	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16987	Exhibit 30	Beaman, Jason Exhibit 30	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
16988	Exhibit 1	Kolodny, Andrew Exhibit 1		
16989	Exhibit 2	Kolodny, Andrew Exhibit 2		
16990	Exhibit 3	Kolodny, Andrew Exhibit 3		
16991	Exhibit 4	Kolodny, Andrew Exhibit 4		
16992	Exhibit 5	Kolodny, Andrew Exhibit 5		
16993	Exhibit 6	Kolodny, Andrew Exhibit 6		
16994	Exhibit 7	Kolodny, Andrew Exhibit 7		
16995	Exhibit 8	Kolodny, Andrew Exhibit 8		
16996	Exhibit 9	Kolodny, Andrew Exhibit 9		
16997	Exhibit 10	Kolodny, Andrew Exhibit 10		
16998	Exhibit 11	Kolodny, Andrew Exhibit 11		
16999	Exhibit 12	Kolodny, Andrew Exhibit 12		
17000	Exhibit 13	Kolodny, Andrew Exhibit 13		

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
17001	Exhibit 14	Kolodny, Andrew Exhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17002	Exhibit 15	Kolodny, Andrew Exhibit 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17003	Exhibit 16	Kolodny, Andrew Exhibit 16		
17004	Exhibit 17	Kolodny, Andrew Exhibit 17		
17005	Exhibit 18	Kolodny, Andrew Exhibit 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17006	Exhibit 19	Kolodny, Andrew Exhibit 19		
17007	Exhibit 31	Beaman, Jason Exhibit 31	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17008	Exhibit 32	Beaman, Jason Exhibit 32	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17009	Exhibit 33	Beaman, Jason Exhibit 33	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17010	Exhibit 34	Beaman, Jason Exhibit 34	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17011	Exhibit 35	Beaman, Jason Exhibit 35	Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17012	Exhibit 36	Beaman, Jason Exhibit 36	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17013	Exhibit 37	Beaman, Jason Exhibit 37	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17014	Exhibit 38	Beaman, Jason Exhibit 38	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
17015	Exhibit 39	Beaman, Jason Exhibit 39	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17016	Exhibit 40	Beaman, Jason Exhibit 40	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17017	Exhibit 1	Duncan, John Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17018	Exhibit 2	Duncan, John Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17019	Exhibit 3	Duncan, John Exhibit 3	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17020	Exhibit 4	Duncan, John Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17021	Exhibit 5	Duncan, John Exhibit 5		
17022	Exhibit 6	Duncan, John Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17023	Exhibit 7	Duncan, John Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17024	Exhibit 8	Duncan, John Exhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17025	Exhibit 9	Duncan, John Exhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17026	Exhibit 10	Duncan, John Exhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
17027	Exhibit 1	Croff, JulieExhibit 1		
17028	Exhibit 2	Croff, JulieExhibit 2		
17029	Exhibit 3	Croff, JulieExhibit 3		
17030	Exhibit 1	Ruhm, ChristopherExhibit 1		
17031	Exhibit 2	Ruhm, ChristopherExhibit 2		
17032	Exhibit 3	Ruhm, ChristopherExhibit 3	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17033	Exhibit 4	Ruhm, ChristopherExhibit 4		
17034	Exhibit 5	Ruhm, ChristopherExhibit 5		
17035	Exhibit 6	Ruhm, ChristopherExhibit 6		
17036	Exhibit 7	Ruhm, ChristopherExhibit 7	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17037	Exhibit 8	Ruhm, ChristopherExhibit 8	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17038	Exhibit 1	Rojas, JulioExhibit 1		
17039	Exhibit 2	Rojas, JulioExhibit 2	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17040	Exhibit 3	Rojas, JulioExhibit 3		
17041	Exhibit 4	Rojas, JulioExhibit 4		
17042	Exhibit 5	Rojas, JulioExhibit 5		
17043	Exhibit 6	Rojas, JulioExhibit 6	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17044	Exhibit 1	Geiger, JillExhibit 1	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17045	Exhibit 2	Geiger, JillExhibit 2	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17046	Exhibit 3	Geiger, JillExhibit 3	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
17047	Exhibit 4	Geiger, JIIExhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17048	Exhibit 5	Geiger, JIIExhibit 5	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17049	Exhibit 6	Geiger, JIIExhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17050	Exhibit 7	Geiger, JIIExhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17051	Exhibit 8	Geiger, JIIExhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17052	Exhibit 9	Geiger, JIIExhibit 9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17053	Exhibit 10	Geiger, JIIExhibit 10	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17054	Exhibit 11	Geiger, JIIExhibit 11	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17055	Exhibit 12	Geiger, JIIExhibit 12	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17056	Exhibit 13	Geiger, JIIExhibit 13	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17057	Exhibit 14	Geiger, JIIExhibit 14	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
17058	Exhibit 15	Geiger, Jill Exhibit 15	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17059	Exhibit 16	Geiger, Jill Exhibit 16	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17060	Exhibit 17	Geiger, Jill Exhibit 17	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17061	Exhibit 18	Geiger, Jill Exhibit 18	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17062	Exhibit 1	Sharp, Susan Exhibit 1	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17063	Exhibit 2	Sharp, Susan Exhibit 2		
17064	Exhibit 3	Sharp, Susan Exhibit 3		
17065	Exhibit 4	Sharp, Susan Exhibit 4		
17066	Exhibit 1	White, Terri Exhibit 1		
17067	Exhibit 2	White, Terri Exhibit 2	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17068	Exhibit 3	White, Terri Exhibit 3		
17069	Exhibit 4	White, Terri Exhibit 4	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17070	Exhibit 5	White, Terri Exhibit 5		
17071	Exhibit 6	White, Terri Exhibit 6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17072	Exhibit 7	White, Terri Exhibit 7	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
17073	Exhibit 8	White, TerriExhibit 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
17074	Exhibit 9	White, TerriExhibit 9		
17075	Exhibit 10	White, TerriExhibit 10		
17076	Exhibit 11	White, TerriExhibit 11		
17077	Exhibit 12	White, TerriExhibit 12		
17078	Exhibit 13	White, TerriExhibit 13		
17079	Exhibit 14	White, TerriExhibit 14		
17080	Exhibit 15	White, TerriExhibit 15		
17081	Exhibit 16	White, TerriExhibit 16		
17082	Exhibit 17	White, TerriExhibit 17		
18000	Exhibit 1	S. Nicholson's Expert Disclosures	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18001	Exhibit 2	S. Nicholson's Complete File	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18002	Exhibit 1	P. Chintagunta's Expert Disclosures	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18003	Exhibit 2	P. Chintagunta's Complete File	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18004	Exhibit 4	Case Background and Allegations	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18005	Exhibit 5	P. Chintagunta Slides	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18006	Exhibit 1	M. Rosenblatt's Expert Disclosures	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18007	Exhibit 1	J. Ketcham's Expert Disclosures	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
18008	Exhibit 2	List of Materials Referenced	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18009	Exhibit 3	J. Ketcham's Complete File	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18010	Exhibit 4	J. Ketcham Slides	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18011	Exhibit 1	E. Michna's Expert Disclosures	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18012-18639	TEVA_OK_14085612- TEVA_OK_14110360	Materials Relied upon by the Tera and Acquired Actavis Entities' experts in preparing disclosures	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18640	TEVA_OK_14110361	Materials provided by Cornerstone in preparation for deposition.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18641	TEVA_OK_14110384	Materials provided by Cornerstone in preparation for deposition.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18642	TEVA_OK_14110385	Materials provided by Cornerstone in preparation for deposition.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18643	TEVA_OK_14110702	Materials provided by Cornerstone in preparation for deposition.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18644	TEVA_OK_14110703	Materials provided by Cornerstone in preparation for deposition.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18645	TEVA_OK_14112059	Materials provided by Cornerstone in preparation for deposition.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18646	TEVA_OK_01009414	Zimmet Presentation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18647	TEVA_OK_00017574	Zimmet Presentation	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18648	Publicly Available	Aaron S. Kesselheim et al., "A Randomized Study of How Physicians Interpret Research Funding Disclosures," <i>The New England Journal of Medicine</i> , 367(12), pp. 1119-1127	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18649	Publicly Available	Ajay Kalra et al., "Understanding Responses to Contradictory Information About Products," <i>Marketing Science</i> , 30(6), pp. 1098-1114	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18650	Publicly Available	Andrea Coscelli, "The Importance of Doctors' and Patients' Preferences in the Prescription Decision," <i>The Journal of Industrial Economics</i> , 48(3), pp. 349-369	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18651	Publicly Available	Andrew Ching and Masakazu Ishihara, "The Effects of Detailing on Prescribing Decisions Under Quality Uncertainty," <i>Quantitative Marketing Economics</i> , 8(2).	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18652	Publicly Available	Anusua Datta and Dhaval Dave, "Effects of Physician-Directed Pharmaceutical Promotion on Prescription Behaviors: Longitudinal Evidence," <i>Health Economics</i> , 26(4), pp. 450-468	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18653	Publicly Available	Bart J. Bronnenberg and Vijay Mahajan, "Unobserved Retailer Behavior in Multimarket Data: Joint Spatial Dependence in Market Shares and Promotion Variables," <i>Marketing Science</i> , 20(3), pp. 284-299	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18654	Publicly Available	Bradley T. Shapiro, "Positive Spillovers and Free Riding in Advertising of Prescription Pharmaceuticals: The Case of Antidepressants," <i>Journal of Political Economy</i> , 126(1), pp. 381-437	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18655	Publicly Available	Carmen R. Green et al., "Clinical Decision Making in Pain Management: Contributions of Physician and Patient Characteristics to Variations in Practice," <i>The Journal of Pain</i> , 4(1), pp. 29-39	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18656	Publicly Available	Christopher R. Carpenter et al., "Using Publication Metrics to Highlight Academic Productivity and Research Impact," <i>Academic Emergency Medicine</i> , 21(10), pp. 1160-1172	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18657	Publicly Available	Darius Lakdawalla and Tomas Philipson, "Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets," <i>The Journal of Law and Economics</i> , 55(1), pp. 151-187	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18658	Publicly Available	Dhaval Dave and Henry Safter, "Impact of Direct-to-Consumer Advertising on Pharmaceutical Prices and Demand," <i>Southern Economic Journal</i> , 79(1), pp. 97-126	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18659	Publicly Available	Douglas E. Mager and Emily R. Cox, "Relationship Between Generic and Preferred-Brand Prescription Copayment Differentials and Generic Fill Rate," <i>The American Journal of Managed Care</i> , 13(6), pp. 347-352	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18660	Publicly Available	Ernst R. Berndt, "The U.S. Pharmaceutical Industry: Why Major Growth in Times of Cost Containment?," <i>Health Affairs</i> , 20(2), pp. 100-114	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18661	Publicly Available	Fusun F. Gonnul et al., "Promotion of Prescription Drugs and Its Impact on Physicians' Choice Behavior," <i>Journal of Marketing</i> , 65(3), pp. 79-90	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18662	Publicly Available	Glen T. Schunmook et al., "Factors that Influence Prescribing Decisions," <i>The Annals of Pharmacotherapy</i> , 38(4), pp. 557-562	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18663	Publicly Available	Hartkesh S. Nair et al., "Asymmetric Social Interactions in Physician Prescription Behavior: The Role of Opinion Leaders," <i>Journal of Marketing Research</i> , 47(5), pp. 883-895	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18664	Publicly Available	Henry Grabowski et al., "Does Generic Entry Always Increase Consumer Welfare?" <i>Food and Drug Law Journal</i> , 67(3), pp. 373-391	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	
18665	Publicly Available	Henry Grabowski et al., "Returns on Research and Development for 1990s New Drug Introductions," <i>Pharmacoeconomics</i> , 20(3), pp. 11-29	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	
18666	Publicly Available	Ian Larkin et al., "Association Between Academic Medical Center Pharmaceutical Detailing Policies and Physician Prescribing," <i>Journal of the American Medical Association</i> , 317(17), pp. 1785-1795	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	
18667	Publicly Available	Jeffrey R. Lacasse and Jonathan Leo, "Knowledge of Ghostwriting and Financial Conflicts-of-Interest Reduces the Perceived Credibility of Biomedical Research," <i>BMC Research Notes</i> , 4(27), pp. 1-6	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	
18668	Publicly Available	John A. Rizzo, "Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs," <i>The Journal of Law and Economics</i> , 42(1), pp. 89-116	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	
18669	Publicly Available	Jonathan D. Ketcham and Andrew J. Epstein, "Which Physicians are Affected Most by Medicaid Preferred Drug Lists for Statins and Antihypertensives?" <i>Pharmacoeconomics</i> , 24(3), pp. 27-40	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	
18670	Publicly Available	Judie M. Donohue et al., "A Decade of Direct-to-Consumer Advertising of Prescription Drugs," <i>The New England Journal of Medicine</i> , 357(7), pp. 673-681	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	
18671	Publicly Available	Kenneth I. Karim et al., "The Role of the Research-Based Pharmaceutical Industry in Medical Progress in the United States," <i>The Journal of Clinical Pharmacology</i> , 33(5), pp. 412-417	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative, Cumulative, 12 O.S. § 2403, Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18672	Publicly Available	Lisa D. Spiller and Walter W. Wymer, Jr., "Physicians' Perceptions and Uses of Commercial Drug Information Sources: An Examination of Pharmaceutical Marketing to Physicians," <i>Health Marketing Quarterly</i> , 19(1), pp. 91-106	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
18673	Publicly Available	Marc Nerlove and Kenneth J. Arrow, "Optimal Advertising Policy Under Dynamic Conditions," <i>Economica</i> , 29(114), pp. 129-142	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
18674	Publicly Available	Marcus Dillender, "What Happens When the Insurer Can Say No? Assessing Prior Authorization as a Tool to Prevent High-Risk Prescriptions and to Lower Costs," <i>Journal of Public Economics</i> , 165(1), pp. 1-9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
18675	Publicly Available	Michelle Palmer and Rathnam Chaguturu, "Academia-Pharma Partnerships for Novel Drug Discovery: Essential or Nice to Have?," <i>Expert Opinion on Drug Discovery</i> , 12(6), pp. 537-540	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
18676	Publicly Available	Mike Thelwall, "Microsoft Academic Automatic Document Searches: Accuracy for Journal Articles and Suitability for Citation Analysis," <i>Journal of Informetrics</i> , 12(1), pp. 1-9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
18677	Publicly Available	Molly Schnell and Janet Currie, "Addressing the Opioid Epidemic: Is There a Role for Physician Education?" <i>American Journal of Health Economics</i> , 4(3), pp. 383-410	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
18678	Publicly Available	Natalie Mizik and Robert Jacobson, "Are Physicians 'Easy Marks'? Quantifying the Effects of Deftailing and Sampling on New Prescriptions," <i>Management Science</i> , 50(12), pp. 1704-1715	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
18679	Publicly Available	Nora D. Volkow et al., "Characteristics of Opioid Prescriptions in 2009," <i>Journal of the American Medical Association</i> , 305(13), pp. 1299-1301	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	
18680	Publicly Available	Peter S. H. Leffang and Jaap E. Wieringa, "Modeling the Effects of Pharmaceutical Marketing," <i>Marketing Letters</i> , 21(2), pp. 121-133	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403	

Exhibit No.	Pages No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18681	Publicly Available	Pierre Azoulay, "Do Pharmaceutical Sales Respond to Scientific Evidence?" <i>Journal of Economics & Management Strategy</i> , 11(4), pp. 551-594	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18682	Publicly Available	Pradeep K. Chintagunta et al., "Endogeneity and Simultaneity in Competitive Pricing and Advertising: A Logit Demand Analysis," <i>The Journal of Business</i> , 79(6), pp. 2761-2787 at p. 2762.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18683	Publicly Available	Pradeep K. Chintagunta et al., "Information, Learning, and Drug Diffusion: The Case of Cox-2 Inhibitors," <i>Quantitative Marketing & Economics</i> , 7(4), pp. 399-443	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18684	Publicly Available	Puneet Manchanda and Pradeep K. Chintagunta, "Responsiveness of Physician Prescription Behavior to Salesforce Effort: An Individual Level Analysis," <i>Marketing Letters</i> , 15(2-3), pp. 129-145	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18685	Publicly Available	Puneet Manchanda et al., "Response Modeling with Nonrandom Marketing-Mix Variables," <i>Journal of Marketing Research</i> , 41(4), pp. 467-478	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18686	Publicly Available	Ramkumar Janakraman et al., "Physicians' Persistence and Its Implications for Their Response to Promotion of Prescription Drugs," <i>Management Science</i> , 54(6), pp. 1080-1093	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18687	Publicly Available	S. L. Carnay et al., "Pharmaceutical Industry-Sponsored Meetings: Good Value or Just a Free Meal?" <i>Internal Medicine Journal</i> , 31(8), pp. 488-491	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18688	Publicly Available	Sara T.M. Kremer et al., "Generalizations on the Effectiveness of Pharmaceutical Promotional Expenditures," <i>International Journal of Research in Marketing</i> , 25(4), pp. 234-246	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18689	Publicly Available	Scott Pegler and Jonathan Underhill, "Evaluating the Safety and Effectiveness of New Drugs," <i>American Family Physician</i> , 82(1), pp. 53-57	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18690	Publicly Available	Sridhar Narayanan et al., "Temporal Differences in the Role of Marketing Communication in New Product Categories," <i>Journal of Marketing Research</i> , 42(3), pp. 278-290	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18691	Publicly Available	Sriram Venkataraman and Stefan Stremersch, "The Debate on Influencing Doctors' Decisions: Are Drug Characteristics the Missing Link?" <i>Management Science</i> , 53(11), pp.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18692	Publicly Available	Suchin Virabhak and Judith A. Shingole, "Physicians' Prescribing Responses to a Restricted Formulary: The Impact of Medicaid Preferred Drug Lists in Illinois and Louisiana," <i>The American Journal of Managed Care</i> , 11(Special Issue), pp. SP14-SP20	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18693	Publicly Available	Sven E. Hing et al., "Citation Analysis with Microsoft Academic," <i>Scientometrics</i> , 111(1), pp. 371-378	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18694	Publicly Available	T. M. Hayes et al., "Continuing Education for General Practice and the Role of the Pharmaceutical Industry," <i>British Journal of General Practice</i> , 49(341), pp. 510-512	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18695	Publicly Available	Tat Chan et al., "Treatment Effectiveness and Side Effects: A Model of Physician Learning," <i>Management Science</i> , 59(6), pp. 1309-1325	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18696	Publicly Available	Theodore H. Stanley, "The Fentanyl Story," <i>The Journal of Pain</i> , 15(12), pp. 1215-1226	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18697	Publicly Available	Thomas S. Reitor et al., "Effect of Tiered Prescription Copayments on the Use of Preferred Brand Medications," <i>Medical Care</i> , 41(3), pp. 398-406	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18698	Publicly Available	W. Paul McKinney et al., "Attitudes of Internal Medicine Faculty and Residents Toward Professional Interaction with Pharmaceutical Sales Representatives," <i>Journal of the American Medical Association</i> , 264(13), pp. 1693-1697	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18699	Publicly Available	Y. Richard Wang and Mark V. Pauly, "Spillover Effects of Restrictive Drug Formulations on Physician Prescribing Behavior: Evidence from Medicaid," <i>Journal of Economics & Management Strategy</i> , 14(3), pp. 755-773.	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18700	Publicly Available	"2018 PhRMA Annual Membership Survey," PhRMA Report, available at https://www.phrma.org/report/2018-phrma-annual-membership-survey	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18701	Publicly Available	Association of American Medical Colleges, "2011 State Physician Workforce Data Book," available at https://www.aamc.org/download/263512/data/statedata2011.pdf	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18702	Publicly Available	"Actavis Completes Allergen Acquisition," <i>PRNewswire</i> , available at https://www.prnewswire.com/news-releases/actavis-completes-allergen-acquisition-300051633.html	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18703	Publicly Available	"ACTIQ® (fentanyl citrate) oral transmucosal lozenge Medication Guide," available at https://dailymed.nlm.nih.gov/dailymed/druginfo.cfm?setid=90b94524-f913-48b3-3771-7b2fcfd888a	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18704	Publicly Available	Battelle Technology Partnership Practice, "Biopharmaceutical Industry-Sponsored Clinical Trials: Impact on State Economies," PhRMA Report, available at http://phrma-docs.phrma.org/sites/default/files/pdf/biopharmaceutical-industry-sponsored-clinical-trials-impact-on-state-economies.pdf	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18705	Publicly Available	Center for Drug Evaluation and Research, "Approval Package for: Application Number 20-747/S003," available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020747Orig1s003.pdf	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18706	Publicly Available	Centers for Medicare & Medicaid Services, "About Open Payments Data," available at https://openpaymentsdata.cms.gov/about	Hearsay, 12 O.S. § 2802, Relevance, 12 O.S. § 2402, Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18707	Publicly Available	Congressional Budget Office, "Research and Development in the Pharmaceutical Industry," available at https://www.cbo.gov/sites/default/files/109th-congress-2005-2006/reports/10-02-drug-ind.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18708	Publicly Available	Dick R. Witink, "Analysis of ROI for Pharmaceutical Promotion (ARPP)," Working Paper, available at http://course.fh-regensburg.de/kurs_20/kursdateien/2010Analysis_of_ROI.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18709	Publicly Available	FDA, "A Guide to Drug Safety Terms at FDA," available at https://www.fda.gov/downloads/forconsumers/consumerupdates/ucm107976.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18710	Publicly Available	FDA "CFR - Code of Federal Regulations Title 21," available at https://www.accessdata.fda.gov/scripts/cdrh/cdohs/cftr/cfrrsearch.cfm?CFRPart=314&showFR=&subpartNode=21.5.0.1.1.4.8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18711	Publicly Available	FDA, "FDA Announces Enhanced Warnings for Immediate-Release Opioid Pain Medications Related to Risks of Misuse, Abuse, Addiction, Overdose and Death," FDA News Release, available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm491739.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18712	Publicly Available	FDA, "Generic Drug Facts," available at https://www.fda.gov/Drugs/Resources/ForYou/Consumers/BuyingUsingMedicineSafety/Generics/ucm167991.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18713	Publicly Available	FDA, "Generic Drugs Undergo Rigorous FDA Scrutiny," available at https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm340343.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18714	Publicly Available	FDA, "Prescription Drug Advertising: Questions and Answers," available at https://www.fda.gov/drugs/prescription-drug-advertising/prescription-drug-advertising-questions-and-answers	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18715	Publicly Available	FDA, "Questions and Answers: FDA Approves a Class Risk Evaluation and Mitigation Strategy (REMS) for Transmucosal Immediate-Release Fentanyl (TIRF) Medicines," available at https://www.fda.gov/Drugs/DrugSafety/InformationOnlyDrugClass/ucm284717.htm#Q6	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18716	Publicly Available	FDA Presentation, "Transmucosal Immediate-Release Fentanyl (TIRF) REMS," available at https://www.fda.gov/advisory-committees/drug-safety-and-risk-management-advisory-committee/slides-august-3-2018-joint-meeting-drug-safety-and-risk-management-advisory-committee-dsarm-and	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18717	Publicly Available	FDA, "Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS)," available at http://www.accessdata.fda.gov/drugsatfda_docs/remss/TIRF_SS_2015-12-21_REMS_FULL.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18718	Publicly Available	Federal Trade Commission Report, "Authorized Generic Drugs: Short-Term Effects and Long-Term Impact" available at https://www.ftc.gov/sites/default/files/documents/reports/authorized-generic-drugs-short-term-effects-and-long-term-impact-report-federal-trade-commission/authorized-generic-drugs-short-term-effects-and-long-term-impact-report-federal-trade-commission.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18719	Publicly Available	"PENTORA® (fentanyl) buccal tablet Medication Guide," available at https://daily.med.nlm.nih.gov/dailymed/medguide.cfm?setid=8f549d95-985b-f783-1ebbf57bd2ec05	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18720	Publicly Available	"K-OI Management in Pharma and Life Sciences," available at https://www.destinationcrm.com/Articles/ReadArticle.aspx?ArticleID=41973	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.

Exhibit No.	Bates No.	Description	Star's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18721	Publicly Available	Letter from Bob Rappaport (FDA) to Carol S. Marchione (Cephalon), Fentora Approval Letter, available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021947s000_APPROV.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18722	Publicly Available	Letter from Cynthia McCormick (FDA) to Patricia J. Richards (Anesta Corporation), Actiq Approval Letter, available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20747_Actiq_appltr.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18723	Publicly Available	National Center for Biotechnology Information, "PubMed Help," available at https://www.ncbi.nlm.nih.gov/books/NBK3827/	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18724	Publicly Available	NIH U.S. National Library of Medicine, "MEDLINE®: Description of the Database," available at https://www.nlm.nih.gov/bsd/medline.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18725	Publicly Available	"Pharmaceutical Marketing in Perspective: Its Value and Role as One of Many Factors Informing Prescribing," PHRMA, available at http://phrma-docs.phrma.org/sites/default/files/pdf/phrma-marketing_brochure_influences_on_prescribing_final.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18726	Publicly Available	Prescriber's Digital Reference, "Fentanyl/citrate - Drug Summary," available at https://www.pdr.net/drug-summary/Actiq-fentanyl-citrate-1747200	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18727	Publicly Available	Puneet Manchanda and Elisabeth Honka, "The Effects and Role of Direct-to-Physician Marketing in the Pharmaceutical Industry: An Integrative Review," <i>Yale Journal of Health Policy, Law, and Ethics</i> , 5(2), pp. 785-822, available at https://digitalcommons.law.yale.edu/yjple/vol5/iss2/8/	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18728	Publicly Available	QuintilesIMS, "Medical Science Liaisons: A key to driving patient access to new therapies," available at https://www.iquvia.com/-/media/library/white-papers/medical-science-liaisons.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
18729	Publicly Available	Statista, "Top Pharmaceutical Companies' Expenditure on Marketing as a Percentage of Sales in 2013," available at https://www.statista.com/statistics/271794/marketing-expenditure-of-pharmaceutical-companies-in-2009/	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18730	Publicly Available	Scott Neslin Presentation, "ROI Analysis of Pharmaceutical Promotion (RAPP): An Independent Study," available at https://ann.memberclicks.net/assets/documents/RAPP_Study_AMM.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18731	Publicly Available	TIRF REMS Access, "The Transmucosal Immediate Release Fentanyl (TIRF) REMS Access Program Patient-Prescriber Agreement Form," available at https://www.tirfremaccess.com/TirfU/remspdf/ppaf-form.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18732	Publicly Available	TIRF REMS Access, "TIRF REMS Access Program Home," available at https://www.tirfremaccess.com/TirfU/remshome.action	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18733	Publicly Available	T. P. G. M. de Vries et al., "Guide to Good Prescribing: A Practical Manual," World Health Organization DAP No. 94.11, available at https://apps.who.int/medicinedocs/pdf/whozi/p23e/whozip23e.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18734	Publicly Available	U.S. Department of Justice, Drug Enforcement Administration, Diversion Control Division, "Title 21 United States Code (USC) Controlled Substances Act," available at https://www.dea.gov/drug-scheduling	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18735	Publicly Available	U.S. Department of Justice, Drug Enforcement Administration, "Drug Scheduling," available at https://www.dea.gov/drug-scheduling	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18736	Publicly Available	Walgreens, "What is a black box warning on a prescription drug?," available at https://www.walgreens.com/topic/faq/questionandanswer.jsp?questionTierId=900002&faqId=5400004	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.

Exhibit No.	Rates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18737	Publicly Available	Ajay Kaitra et al., "Understanding Responses to Contradictory Information About Products," <i>Marketing Science</i> , 30(6)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18738	Publicly Available	Chad M. Brummert et al., "New Persistent Opioid Use after Minor and Major Surgical Procedures in US Adults," <i>JAMA Surgery</i> , 152(6), pp. 1-9	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18739	Publicly Available	Curtis S. Florence et al., "The Economic Burden of Prescription Opioid Overdose, Abuse and Dependence in the United States, 2013," <i>Medical Care</i> , 54(10)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18740	Publicly Available	Curtis S. Florence et al., online appendix, "Methodological Assumptions," available at http://links.lww.com/MLR/B262	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18741	Publicly Available	Darius Lakdawalla and Tomas Philipson, "Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets," <i>Journal of Law and Economics</i> , 55(1), pp. 151-187	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18742	Publicly Available	Douglas E. Mager and Emily R. Cox, "Relationship Between Generic and Preferred-Brand Prescription Copayment Differentials and Generic Fill Rate," <i>The American Journal of Managed Care</i> , 13(6), pp. 347-352	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18743	Publicly Available	Enno Freye and Joseph Victor Levy, <i>Opioids in Medicine: A Comprehensive Review on the Mode of Action and the Use of Analgesics in Different Pain States</i> , Dordrecht, The Netherlands: Springer	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18744	Publicly Available	Ernst R. Berndt and Joseph P. Newhouse, "Pricing and Reimbursement in US Pharmaceutical Markets," <i>NBER Working Paper</i> , p. 8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18745	Publicly Available	Ernst R. Berndt, "The U.S. Pharmaceutical Industry: Why Major Growth in Times of Cost Containment?," <i>Health Affairs</i> , 20(2), pp. 100-114	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18746	Publicly Available	George Casella and Roger L. Berger "Statistical Inference," Second Edition, Thomson Learning	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18747	Publicly Available	George Psacharopoulos and Harry Antony Patrinos, "Returns to Investment in Education: A Decennial Review of the Global Literature," Policy Research Working Paper 8402, World Bank Education Global Practice, available at http://documents.worldbank.org/curated/en/44521523465644318/pdf/WPS8402.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18748	Publicly Available	Janet Currie and Cathy S. Widom, "Long-Term Consequences of Child Abuse and Neglect on Adult Economic Well-Being," <i>Child Maltreatment</i> , 15(2), pp. 111-120	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18749	Publicly Available	Janet Currie et al., "U.S. Employment and Opioids: Is There a Connection?" National Bureau of Economic Research, available at https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3149264	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18750	Publicly Available	Jay Soong-Jin Lee et al., "New Persistent Opioid Use Among Patients with Cancer After Curative-Intent Surgery," <i>Journal of Clinical Oncology</i> , 33(36), pp. 4042-4053	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18751	Publicly Available	Marcus Dillender, "What Happens When the Insurer Can Say No? Assessing Prior Authorization as a Tool to Prevent High-Risk Prescriptions and to Lower Costs," <i>Journal of Public Economics</i> , 165(1)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18752	Publicly Available	Maria A. Oquendo and Nora D. Volkow, "Suicide: A Silent Contributor to Opioid-Overdose Deaths," <i>New England Journal of Medicine</i> , 378(17), available at https://www.nejm.org/doi/10.1056/NEJMp1801417	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18753	Publicly Available	Maana C. Dabora et al., "Financing and Distribution of Pharmaceuticals in the United States," <i>JAMA</i> , 318(1)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18754	Publicly Available	Nabarin Dasgupta et al., "Opioid Crisis: No Easy Fix to Its Social and Economic Determinants," <i>American Journal of Public Health</i> , 108(2)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18755	Publicly Available	Pradeep K. Chintagunta et al., "Information Learning and Drug Diffusion: The Case of Cox-2 Inhibitors." Quantitative Marketing and Economics, 7(4)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18756	Publicly Available	Priscilla Hunt et al., "The Price of Justice: New National and State-Level Estimates of the Judicial and Legal Costs of Crime to Taxpayers," <i>American Journal of Criminal Justice</i> , 42(2), pp. 231-254	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18757	Publicly Available	Raj Chetty et al., "The Association Between Income and Life Expectancy in the United States, 2001-2014," <i>JAMA</i> , 315(16)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18758	Publicly Available	Sachin Kamal-Bahl and Becky Briesacher, "How Do Incentive-Based Formulas Influence Drug Selection And Spending For Hypertension?," <i>Health Affairs</i> , 23(1), pp. 227-236	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18759	Publicly Available	Stanley S. Wallack et al., "Health Plans' Strategies to Control Prescription Drug Spending," <i>Health Affairs</i> , 23(6), pp. 141-148	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18760	Publicly Available	Tat Chan et al., "Treatment Effectiveness and Side Effects: A Model of Physician Learning," <i>Management Science</i> , 59(6)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18761	Publicly Available	Thomas C. Buchtmueller and Colleen Carey, "The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare," <i>American Economic Journal: Economic Policy</i> , 10(1), pp. 77-112	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18762	Publicly Available	Thomas S. Reitor et al., "Effect of Tiered Prescription Copayments on the Use of Preferred Brand Medications," <i>Medical Care</i> , 41(3)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18763	Publicly Available	W. Kip Viscusi, "The Value of Life in Legal Contexts: Survey and Critique," <i>American Law and Economics Review</i> , 2(1), pp. 195-222	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18764	Publicly Available	Zhou, Chao, et al., "Payments for Opioids Shifted Substantially to Public and Private Insurers While Consumer Spending Declined, 1999-2012," <i>Health Affairs</i> , 35(5)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18765	Publicly Available	"Using International Classification of Diseases (ICD) Codes to Assess Opioid-Related Overdose Deaths," Substance Abuse and Mental Health Services Administration, available at https://nmpnc.org/wp-content/uploads/2019/01/using-icd-10-codes-to-assess-opioid-related-overdose-deaths.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18766	Publicly Available	Adam J. Fein, "Modern Distribution Management (MDM), 2016 MDM market leaders: top pharmaceutical distributors," MDM, available at https://www.mdm.com/2016-top-pharmaceuticals-distributors	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18767	Publicly Available	Bipartisan Policy Center, "Tracking Federal Funding to Combat the Opioid Crisis," available at https://bipartisanpolicy.org/wp-content/uploads/2019/03/Tracking-Federal-Funding-to-Combat-the-Opioid-Crisis.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18768	Publicly Available	CMS, "Opioid Misuse Strategy 2016," available at https://www.cms.gov/Outreach-and-Education/Outreach/Partnerships/Downloads/IMS-Opioid-Misuse-Strategy-2016.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18769	Publicly Available	DEA Form Reference ID: 4148977, "The TIRF REMS Access Program: Knowledge Assessment," available at https://www.accessdata.fda.gov/drugsatfda_docs/reams/TIRF_2017-09-07_Knowledge_Assessment.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18770	Publicly Available	DEA, "Justice Department, DEA propose significant opioid manufacturing reduction in 2019," available at https://www.dea.gov/press-releases/2018/08/16/justice-department-dea-propose-significant-opioid-manufacturing-reduction	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Tera exhibit because J&J and Janssen have not had the opportunity to review them)
18771	Publicly Available	DEA, "Missions," available at https://www.dea.gov/mission	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18772	Publicly Available	DEA, "Drug Scheduling," available at https://www.dea.gov/drug-scheduling	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18773	Publicly Available	DEA, "Fentanyl: (Trade Names: Actiq®, Fentora™, Duragesic®)," available at https://www.deadiversion.usdoj.gov/drug_cen_info/fentanyl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18774	Publicly Available	DEA, "Practitioner's Manual: An Informational Outline of the Controlled Substances Act," United States Department of Justice Report, available at https://www.deadiversion.usdoj.gov/pubs/manuel/pract/index.html	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18775	Publicly Available	Department of Justice: U.S. Attorney's Office, Northern District of Ohio, October 1, 2018, available at https://www.justice.gov/usao-ndoh/pr/justice-department-awards-18-million-support-data-sharing-drug-courts-and-other	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18776	Publicly Available	FDA, "A Guide to Drug Safety: Terms at FDA," "Consumer Health Information Report"	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18777	Publicly Available	FDA, "Actiq®," available at https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/207471bl.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18778	Publicly Available	FDA, "Approved Risk Evaluation and Mitigation Strategies (REMS)," available at https://www.accessdata.fda.gov/scripts/cder/rem/index.cfm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18779	Publicly Available	FDA, "Development & Approval Process (Drugs)," available at https://www.fda.gov/Drugs/Development/ApprovalProcess/default.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18780	Publicly Available	FDA, "Drug Approval Process," available at https://www.fda.gov/downloads/drugs/ressources/foryou/consumers/ucm284393.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18781	Publicly Available	FDA, "Generic Drugs Undergo Rigorous FDA Scrutiny," available at https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm340343.htm	Hearsey, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsey, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18782	Publicly Available	FDA, "Timeline of Selected FDA Activities and Significant Events Addressing Opioid Misuse and Abuse," available at https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM566985.pdf	Hearsey, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsey, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18783	Publicly Available	FDA, "Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS)," available at https://www.accessdata.fda.gov/drugsatfda_docs/remis/TIRF_2017-09-07_REMS_Document.pdf	Hearsey, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsey, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18784	Publicly Available	FDA, "Transmucosal Immediate-Release Fentanyl (TIRF) Medicines," available at https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm282110.htm	Hearsey, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsey, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18785	Publicly Available	FDA, "What Does FDA Inspect?," available at https://www.fda.gov/AboutFDA/Transparency/Basics/ucm194888.htm	Hearsey, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsey, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18786	Publicly Available	FDA, "What's in a REMS?," available at https://www.fda.gov/Drugs/DrugSafety/REMS/ucm592636.htm	Hearsey, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsey, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18787	Publicly Available	FDA, Fentora Approval Letter, available at https://www.accessdata.fda.gov/drugsatfda_docs/applletter/2006/021947s0001tr.pdf	Hearsey, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18788	Publicly Available	Fentora, "Highlights of Prescribing Information," available at http://www.fentora.com/pdfs/pdf100_prescribing_info.pdf	Hearsey, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18789	Publicly Available	Jane Tilly et al., "The Opioid Public Health Emergency and Older Adults," available at http://www.nasund.org/hcbs/article/opioid-public-health-emergency-and-older-adult	Hearsey, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsey, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18790	Publicly Available	Jessica Webster Sendra, "For 1 in 10 Cancer Patients, Surgery Means Opioid Dependence," Michigan Health Lab, available at https://lablog.uofmhealth.org/rounds/for-1-10-cancer-patients-surgery-means-opioid-dependence	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18791	Publicly Available	Julia Zur and Jennifer Tobert, "The Opioid Epidemic and Medicaid's Role in Facilitating Access to Treatment," The Henry J. Kaiser Family Foundation, available at https://www.kff.org/medicaid/issue-brief/the-opioid-epidemic-and-medicoids-role-in-	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18792	Publicly Available	Kaiser Family Foundation, "Follow the Pill: Understanding the U.S. Commercial Pharmaceutical Supply Chain," available at https://www.kff.org/wp-content/uploads/2013/01/follow-the-pill-understanding-the-u-s-commercial-pharmaceutical-supply-chain-report.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18793	Publicly Available	Kaiser Family Foundation, "2016 Employer Health Benefits Annual Survey," available at http://files.kff.org/attachment/Report-Employer-Health-Benefits-2016-Annual-Survey	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18794	Publicly Available	Karen A. Goldman et al., "Authorized Generic Drugs: Short-Term Effects and Long-Term Impact," Federal Trade Commission Report, available at https://www.ftc.gov/sites/default/files/documents/reports/authorized-generic-drugs-short-term-effects-and-long-term-impact-report-federal-trade-commission/authorized-generic-drugs-short-term-effects-and-long-term-impact-report-federal-trade-commission.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18795	Publicly Available	Michelle Llamas, "Black Box Warnings," Drugwatch, available at https://www.drugwatch.com/da/black-box-warnings/	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18796	Publicly Available	Nadia Kounang, "FDA Requires 'Black Box' Warning on Painkillers." <i>CNN</i> , available at https://www.cnn.com/2016/03/22/health/fda-opioid-black-box-warning/index.html	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18797	Publicly Available	Ohio Bureau of Workers' Compensation Final Rule 4123-6-21.4 ("Coordinated services program"), available at https://www.bwc.ohio.gov/downloads/blank.pdf/OAC4123-6-21.4.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18798	Publicly Available	Ohio Department of Medicaid, "Information on the Coordinated Service Program," available at https://pharmacy.medicaid.ohio.gov/sites/default/files/2019%20CSP%20Brochure.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18799	Publicly Available	Paatip K. Muburi et al., "Associations of Nonmedical Pain Reliever Use and Initiation of Heroin Use in the United States." Center for Behavioral Health Statistics and Quality, available at https://www.samhsa.gov/data/sites/default/files/DR006/DR006/nonmedical-pain-reliever-use-2013.htm	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18800	Publicly Available	PwC, "How can pharmaceutical and life sciences companies monitor their wholesalers to minimise financial losses and distribution risks?," Global Pharmaceuticals and Life Sciences Industry Group, available at https://www.pwc.com/gx/en/pharma-life-sciences/pdf/pwc-pharma-wholesaler.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18801	Publicly Available	Robin Gherner and Lincoln Groves, "The Opioid Crisis and Economic Opportunity: Geographic and Economic Trends," U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation Research Brief, available at https://aspe.hhs.gov/system/files/pdf/259261 .	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18802	Publicly Available	U.S. Department of Health and Human Services, "Addressing Prescription Drug Abuse in the United States: Current Activities and Future Opportunities," available at https://www.cdc.gov/drugoverdose/pdf/hhs-prescription_drug_abuse_report_09_2013.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18803	Publicly Available	World Health Organization Report, "Guide to Good Prescribing: A Practical Manual," Document WHO/DAP/94.11, available at https://apps.who.int/medicinedocs/pdf/whozi/p23e/whozip23e.pdf	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18804	Publicly Available	American Pain Foundation, "Treatment Options: A Guide for People Living with Pain", and Webster, Lynn R. and M. Beth Dove, "Optimizing Opioid Treatment for Breakthrough Pain," 2007. www.medscape.org/viewarticle/563417	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18805	Publicly Available	Abby Alpert et al., "Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids," <i>American Economic Journal: Economic Policy</i> 10, no. 4, pp. 1000-1017.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18806	Publicly Available	Aleme Kennedy-Handricks et al., "Opioid Overdose Deaths and Florida's Crackdown on Pill Mills," <i>American Journal of Public Health</i> 106, no. 2, pp. 291-297	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18807	Publicly Available	Alex Hollingsworth et al., "Macroeconomic Conditions and Opioid Abuse," <i>Journal of Health Economics</i> 56, pp. 222-233	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18808	Publicly Available	Amitabh Chandra and Jonathan Skinner, "Technology Growth and Expenditure Growth in Health Care," <i>Journal of Economic Literature</i> 50, no. 3, pp. 645-680	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18809	Publicly Available	Arca M. Grecu et al., "Mandatory Access Prescription Drug Monitoring Programs and Prescription Drug Abuse," <i>Journal of Policy Analysis and Management</i> 38, no. 1, pp. 181-209	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18810	Publicly Available	Andrew Gelman and Jonathan Auerbach, "Age-Aggregation Bias in Mortality Trends," <i>Proceedings of the National Academy of Sciences</i> 113, no. 7, pp.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18811	Publicly Available	Andrew J. Epstein and Jonathan D. Keckham, "Information Technology and Agency in Physicians' Prescribing Decisions," <i>The RAND Journal of Economics</i> 45, no. 2, pp. 422-448	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18812	Publicly Available	Andrew Rhodes and Chris M. Wilson, "False Advertising," <i>The RAND Journal of Economics</i> 49, no. 2, pp. 348-369	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.
18813	Publicly Available	Andrew Rosenblum et al., "Opioids and the Treatment of Chronic Pain: Controversies, Current Status, and Future Directions," <i>Experimental Clinical Psychopharmacology</i> 16, no. 5, pp. 405-416	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18814	Publicly Available	Andrew Wilcock and Robert Twycross eds., "Therapeutic Reviews," <i>Journal of Pain and Symptom Management</i> 44, no. 1, pp. 131-149	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18815	Publicly Available	Anne Case and Angus Deaton, "Deaths of Despair Redux: A Response to Christopher Ruhm"	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18816	Publicly Available	Anne Case and Angus Deaton, "Mortality and Morbidity in the 21st Century," Brookings Papers on Economic Activity BPEA Conference Drafts	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18817	Publicly Available	Anne Schuchat et al., "New Data on Opioid Use and Prescribing in the United States," <i>JAMA</i> 318, no. 5, pp. 425-426	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18818	Publicly Available	Amuj Shah et al., "Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use — United States, 2006–2015," <i>CDC Morbidity and Mortality Weekly Report</i> 66, no. 10, pp. 265–268	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18819	Publicly Available	Anusua Datta and Dhaval Dave, "Effects of Physician-Directed Pharmaceutical Promotion on Prescription Behaviors: Longitudinal Evidence," <i>Health Economics</i> 26, pp. 450-468	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18820	Publicly Available	Aparna Soni, "Health Insurance, Price Changes, and the Demand for Pain Relief Drugs: Evidence from Medicare Part D." Working Paper	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18821	Publicly Available	Brenda R. Motheral, "Pharmaceutical Step-Therapy Interventions: A Critical Review of the Literature," <i>Journal of Managed Care Pharmacy</i> 17, no. 2, pp. 143-155	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18822	Publicly Available	Burton A. Weisbrod, "The Health Care Quadrilemma: An Essay on Technological Change, Insurance, Quality of Care, and Cost Containment," <i>Journal of Economic Literature</i> 29, no. 2, pp. 523-552	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18823	Publicly Available	C. Lee Ventola, "Off-Label Drug Information: Regulation, Distribution, Evaluation, and Related Controversies," <i>Pharmacy & Therapeutics</i> 34, no. 8, pp. 428-449	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18824	Publicly Available	Chao Zhou et al., "Payments for Opioids Shifted Substantially to Public and Private Insurers While Consumer Spending Declined, 1999-2012," <i>Health Affairs</i> 35, no. 5, pp. 824-831a	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18825	Publicly Available	Christopher Jones, "Heroin Use and Heroin Use Risk Behaviors among Nonmedical Users of Prescription Opioid Pain Relievers - United States, 2002-2004 and 2008-2010." <i>Drug and Alcohol Dependence</i> 132, pp. 95-100	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18826	Publicly Available	Christopher M. Wittich et al., "Ten Common Questions (and Their Answers) about Off-Label Drug Use." <i>Mayo Clinic Proceedings</i> 87, no. 10, pp. 982-990	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18827	Publicly Available	Corey S. Davis et al., "Evolution and Convergence of State Laws Governing Controlled Substance Prescription Monitoring Programs, 1998-2011," <i>American Journal of Public Health</i> 104, no. 8, pp. 1389-1395	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18828	Publicly Available	David C. Radley et al., "Off-Label Prescribing among Office-Based Physicians," <i>Archives of Internal Medicine</i> 166, pp. 1021-1026	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18829	Publicly Available	David M. Cutler et al., "Explaining The Slowdown In Medical Spending Growth Among The Elderly, 1999-2012," <i>Health Affairs</i> 38, no. 2, pp. 222-229	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18830	Publicly Available	David Powell et al., "How Increasing Medical Access to Opioids Contributes to the Opioid Epidemic: Evidence from Medicare Part D," Working Paper	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18831	Publicly Available	Davina C. Ling et al., "Deregulation Direct-to-Consumer Marketing of Prescription Drugs: Effects on Prescription and Over-the-Counter Product Sales," <i>The Journal of Law and Economics</i> 45, no. S2, pp. 691-723	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18832	Publicly Available	Deborah Dowell et al., "CDC Guideline for Prescribing Opioids for Chronic Pain – United States, 2016," <i>CDC Morbidity and Mortality Weekly Report</i> 65, no. 1, pp. 1-49	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18833	Publicly Available	Deborah Dowell et al., "Mandatory Provider Review and Pain Clinic Laws Reduce the Amounts of Opioids Prescribed and Overdoes Death Rates," <i>Health Affairs</i> 35, no. 10, pp. 1876-1883	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18834	Publicly Available	Dhaval Dave and Henry Saffier, "Impact of Direct-to-Consumer Advertising on Pharmaceutical Prices and Demand," <i>Southern Economic Journal</i> 79, no. 1, pp. 97-126	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18835	Publicly Available	Douglas E. Mager and Emily R. Cox, "Relationship Between Generic and Preferred-Brand Prescription Copayment Differentials and Generic Fill Rate," <i>The American Journal of Managed Care</i> 13, no. 6, pp. 347-352	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18836	Publicly Available	Edward L. Glaeser and Bruce Sacerdote, "Why Is There More Crime in Cities?" <i>The Journal of Political Economy</i> 107, no. S6, pp. S225-S258	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18837	Publicly Available	E. Ray Dorsey et al., "Impact of FDA Black Box Advisory on Antipsychotic Medication Use," <i>Archives of Internal Medicine</i> 170, no. 1, pp. 96-103	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18838	Publicly Available	Eileen Meara et al., "State Legal Restrictions and Prescription-Opioid Use among Disabled Adults," <i>The New England Journal of Medicine</i> 375, no. 1, pp. 44-53	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18839	Publicly Available	Erin Cavusgil et al., "Late Entrant Over-the-Counter and Rx Market Entry Strategies: An Investigation in the Pharmaceutical Industry," <i>International Journal of Pharmaceutical and Healthcare Marketing</i> 5, no. 2, pp. 79-98	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18840	Publicly Available	Ernst R. Berndt, "To Inform or Persuade? Direct-to-Consumer Advertising of Prescription Drugs," <i>The New England Journal of Medicine</i> 352, no. 4, pp. 325-328	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18841	Publicly Available	Ernst R. Berndt et al., "Information, Marketing, and Pricing in the U.S. Anticancer Drug Market," <i>The American Economic Review</i> 85, no. 2, pp. 100-105	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18842	Publicly Available	Frank Chaloupka, "Rational Addictive Behavior and Cigarette Smoking," <i>The Journal of Political Economy</i> 99, no. 4, pp. 722-742	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18843	Publicly Available	George J. Stigler, "The Economics of Information," <i>The Journal of Political Economy</i> 69, no. 3, pp. 213-225	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18844	Publicly Available	Gery P. Guy Jr. et al., "Vital Signs: Changes in Opioid Prescribing in the United States, 2006–2015," <i>CDC Morbidity and Mortality Weekly Report</i> 66, no. 26, pp. 697–704	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18845	Publicly Available	Guohua Li et al., "Prescription Drug Monitoring and Drug Overdose Mortality," <i>Injury Epidemiology</i> 1, no. 9, pp. 1–8	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18846	Publicly Available	Hawre Jalal et al., "Changing Dynamics of the Drug Overdose Epidemic in the United States from 1979 through 2016," <i>Science</i> 361, no. 1184	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18847	Publicly Available	Hefei Wen et al., "States with Prescription Drug Monitoring Mandates Saw Reduction in Opioids Prescribed to Medicaid Enrollees," <i>Health Affairs</i> 36, no. 4, pp. 733–741	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18848	Publicly Available	Hilary Aroke et al., "Estimating the Direct Costs of Outpatient Opioid Prescriptions: A Retrospective Analysis of Data from the Rhode Island Prescription Drug Monitoring Program," <i>Journal of Managed Care & Specialty Pharmacy</i> 24, no. 3, pp. 214–224a	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18849	Publicly Available	James C. Robinson, "Consolidation and the Transformation of Competition in Health Insurance," <i>Health Affairs</i> 23, no. 6, pp. 11–24	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18850	Publicly Available	James H. Stock and Mark W. Watson, <i>Introduction to Econometrics</i> , Third Edition (Boston, MA: Addison-Wesley)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18851	Publicly Available	Jane C. Ballantyne and Jianren Mao, "Opioid Therapy for Chronic Pain," <i>The New England Journal of Medicine</i> 349, no. 20, pp. 1943–1953	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18852	Publicly Available	Jay M. Margolis et al., "Effects of a Medicaid Prior Authorization Policy for Pregabalin," <i>The American Journal of Managed Care</i> 15, no. 10, pp. e95–e102	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18853	Publicly Available	Jean-Pierre Dubé et al., "An Empirical Model of Advertising Dynamics," <i>Quantitative Marketing and Economics</i> 3, pp. 107-144	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18854	Publicly Available	Jeffrey M. Wooldridge, <i>Introductory Econometrics: A Modern Approach</i> , Fifth Edition (Mason, OH: South-Western)	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18855	Publicly Available	Joanne E. Brady et al., "Prescription Drug Monitoring and Dispensing of Prescription Opioids," <i>Public Health Reports</i> 129, pp. 139-147	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18856	Publicly Available	John A. Rizzo, "Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs," <i>The Journal of Law and Economics</i> 42, no. 1, pp. 89-116	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18857	Publicly Available	John Bian et al., "Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome," <i>Journal of Clinical Oncology</i> 35, no. 17, pp. 1945-1951	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18858	Publicly Available	John Cawley et al., "The Effect of Deceptive Advertising on Consumption of the Advertised Good and Its Substitutes: The Case of Over-the-Counter Weight Loss Products," NBER Working Paper No. 18863	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18859	Publicly Available	John K. Gorman et al., "Chapter 24: Health Plans and Medicare" in <i>Essentials of Managed Health Care</i> , Sixth Edition, ed. Peter R. Kongsvedt (Burlington, MA: Jones & Bartlett Learning), pp. 501-506	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18860	Publicly Available	Jonathan D. Ketcham and Andrew J. Epstein, "Which Physicians are Affected Most by Medicaid Preferred Drug Lists for Status and Antihypertensives?" <i>Pharmacoeconomics</i> 24, no. 3, pp. 27-40	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18861	Publicly Available	Jonathan D. Ketcham and Kosali I. Simon, "Medicare Part D's Effects on Elderly Patients' Drug Costs and Utilization," <i>American Journal of Managed Care</i> 14, no. 11, pp. SP14-SP22	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18862	Publicly Available	Jonathan Gruber and Botond Köszegi, "Is Addiction 'Rational'? Theory and Evidence," <i>The Quarterly Journal of Economics</i> 116, no. 4, pp. 1261-1303	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18863	Publicly Available	Jonathan Skinner and Douglas Starger, "Technology Diffusion and Productivity Growth in Health Care," <i>The Review of Economics and Statistics</i> 97, no. 5, pp. 951-964	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18864	Publicly Available	Joseph P. Newhouse, "Medical Care Costs: How Much Welfare Loss?" <i>Journal of Economic Perspectives</i> 6, no. 3, pp. 3-21	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18865	Publicly Available	Julie M. Donohue and Ernst R. Berndt, "Effects of Direct-to-Consumer Advertising on Medication Choice: The Case of Antidepressants," <i>Journal of Public Policy & Marketing</i> 23, no. 2, pp. 115-127	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18866	Publicly Available	Keith B. Lefler, "Persuasion or Information? The Economics of Prescription Drug Advertising," <i>The Journal of Law and Economics</i> 24, no. 1,	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18867	Publicly Available	Kerwin Kofi Charles et al., "The Transformation of Manufacturing and the Decline in U.S. Employment," NBER Working Paper No. 24468	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18868	Publicly Available	Kevin E. Vowles et al., "Rates of Opioid Misuse, Abuse, and Addiction in Chronic Pain: A Systematic Review and Data Synthesis," <i>PAIN</i> 156, no. 4, pp. 569-576	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18869	Publicly Available	Kyary K. Rigg et al., "Prescription Drug Abuse & Diversion: Role of the Pain Clinic," <i>Journal of Drug Issues</i> 40, no. 3, pp. 681-702	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Pages No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18870	Publicly Available	Lainie Rutkow et al., "Effect of Florida's Prescription Drug Monitoring Program and Pill Mill Laws on Opioid Prescribing and Use," <i>JAMA Internal Medicine</i> 175, no. 10, pp. 1642-1649	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18871	Publicly Available	Lance Lochner and Enrico Moretti, "The Effect of Education on Crime: Evidence from Prison Inmates, Arrests, and Self-Reports," NBER Working Paper No. 8605	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18872	Publicly Available	Laurence C. Baker et al., "The Effects of Medicare Advantage on Opioid Use," NBER Working Paper No. 25327	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18873	Publicly Available	Linda S. Tyler et al., "ASHP Guidelines on the Pharmacy and Therapeutics Committee and the Formulary System," <i>American Journal of Health-System Pharmacists</i> 65, pp. 166-175	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18874	Publicly Available	Liran Einav et al., "Is American Pet Health Care (Also) Uniquely Inefficient? <i>The American Economic Review</i> 107, no. 5, pp. 491-495	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18875	Publicly Available	M. Soledad Cepeda et al., "ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes," <i>Pain Medicine</i> 18, pp. 78-85	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18876	Publicly Available	Marc Nerlove and Kenneth J. Arrow, "Optimal Advertising Policy under Dynamic Conditions," <i>Economica</i> 29, no. 114, pp. 129-142	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18877	Publicly Available	Marcus Dillender, "What Happens When the Insurer Can Say No? Assessing Prior Authorization as a Tool to Prevent High-Risk Prescriptions and to Lower Costs," <i>Journal of Public Economics</i> 165, pp.	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18878	Publicly Available	Marianne Bertrand et al., "How Much Should We Trust Differences-In-Differences Estimates?" <i>The Quarterly Journal of Economics</i> 119, no. 1, pp. 249-275	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	

Exhibit No.	Bates No.	Description	State's Objections	J&J and Janssen's objections (J&J and Janssen reserve the right to object at trial to any Teva exhibit because J&J and Janssen have not had the opportunity to review them)
18879	Publicly Available	Martha M. Rumore and F. Randy Vogenberg, "PPBM P&T Practices: The HEAT Initiative is Gaining Momentum," <i>Health Care & Law</i> 42, no. 5, pp. 330-335	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18880	Publicly Available	Meredith Noble et al., "Long-Term Opioid Management for Chronic Noncancer Pain," <i>Cochrane Database of Systematic Reviews</i> , Issue 1, pp. 1-69	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18881	Publicly Available	Michael A. Morrissey and John Cawley, "Health Economists' Views of Health Policy," <i>Journal of Health Politics, Policy and Law</i> 33, no. 4, pp. 707-724	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18882	Publicly Available	Michael E. Chernew and Joseph P. Newhouse, "Chapter One: Health Care Spending Growth" in <i>Handbook of Health Economics</i> Volume 2, eds. Mark Pauly, Thomas McGuire, Pedro Barros (Amsterdam: Elsevier B.V.), pp. 1-43	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18883	Publicly Available	Molly Schnell and Janet Currie, "Addressing the Opioid Epidemic: Is There a Role for Physician Education?" <i>American Journal of Health Economics</i> 4, no. 3, pp. 383-410	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18884	Publicly Available	Murray Aitken et al., "Has the Era of Slow Growth for Prescription Drug Spending Ended?" <i>Health Affairs</i> 35, no. 9, pp. 1595-1603	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18885	Publicly Available	Natalie Mizlik and Robert Jacobson, "Are Physicians 'Easy Marks'? Quantifying the Effects of Detailing and Sampling on New Prescriptions," <i>Management Science</i> 50, no. 12, pp. 1704-1715	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18886	Publicly Available	Nora D. Volkow and A. Thomas McLellan, "Opioid Abuse in Chronic Pain - Misconceptions and Mitigation Strategies," <i>The New England Journal of Medicine</i> 374, no. 13, pp. 1253-1263	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	
18887	Publicly Available	Pablo Fainzyber et al., "Inequality and Crime," <i>The Journal of Law and Economics</i> 45, no. 1, pp. 1-39	Hearsay, 12 O.S. § 2802; Relevance, 12 O.S. § 2402; Speculative; Cumulative, 12 O.S. § 2403; Confusion/prejudice, 12 O.S. § 2403.	